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CHAPTER 1: BIOMATERIAL APPROACHES TO NERVE REGENERATION
What Is Spinal Cord Injury?
Prevalence and Cost
Spinal cord injury (SCI) is defined by the Center for Disease Control, 1990 Case
definition, as, “An acute traumatic lesion of the neural elements in the spinal canal,
resulting in temporary or permanent sensory deficit, motor deficit, or bowel/bladder
dysfunction.” [5]. Falls and road injuries are considered to be the leading causes of SCI
[6, 7], however the prevalence of SCI is difficult define; different hospitals may have
different classification systems and different injuries may lead to different diagnoses[5, 6].
For instance, accidents that cause SCI but also result in death may not be classified as
such [5]. However, there are several recent sources that give an idea of what the statistics
are for the United States as well as the world at large.
Singh et al. 2014, used several databases to combine and examine data from SCI
reviews [5]. Singh et al found that many different factors affect SCI incidence and
reporting of SCI varies, so it is more accurate to give region or city specific statistics,
rather than to determine an overall average [5]. The United States incident of SCI from
1970 to 1977 was determined to be 40.1 per million people [5]. However, more recent
studies in specific locations found that Alaska’s SCI incident to be 83 per million from
1991 to 1993, while Oklahoma’s SCI incident was 40 per million from 1988 to 1990 [5].
The National Spinal Cord Injury Statistical Center, Birmingham, Alabama, 2019 [8]
is a coalition of spinal cord injury centers across the United States that all share their SCI
data. Though the centers likely to join the coalition may be known for their medical
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prowess and may be more likely to attract SCI patients and thus introduce bias, it is one
of the largest comparable databases available. The numbers that they provide are 17,730
new cases of SCI per year (i.e. incidence), with a prevalence of 291,000 people in the
United States [8]. Globally, the World Health Organization estimates SCI incidence to
250,000 to 500,000 people per year, while the GBD 2016 Traumatic Brain Injury and
Spinal Cord Injury Collaborators recently published an estimated 0.78 billion to 1.16 billion
new cases of SCI per year, with an overall prevalence of 27.04 million world-wide [6, 9].
SCI tends to introduce and exacerbate prevalence of other health issues such as
high blood pressure, obesity, depression and anxiety, chronic fatigue, lung infection and
disease, as well as complications from pressure sores, among many other issues; these
issues tend to lead to reduced life expectancy[10-23]. As an additional burden, it is
estimated that the individual cost of health care after SCI is $2-4 million per year [7].
Current clinical treatments and pre-clinical studies
There is currently no gold standard of care for spinal cord injury, though there is
a focus on reducing the inflammation response as soon as possible after injury [7, 9,
24]. Methylprednisolone (MP) and controlled hypothermia are currently implemented,
but neither are recommended; MP can sometimes reduce the inflammation response at
the risk of compromising the immune system and increased side effects [7, 24] , and
there is little evidence to suggest that hypothermia alone makes a reliable impact [7,
25]. There are several treatments that are under investigation, which can be categorized
as neuroprotective and/or neuroregenerative [7].
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Neuroprotective strategies involves pharmacological interventions with the
intended effects: to reduce inflammation (MP, immunosuppressants such as minocycline
and cyclosporine A, and hypothermia), prevent neuron overstimulation and apoptosis
(magnesium, riluzole, nimodipine), counteract oxidative damage (tirilizad), and increase
growth factor effectiveness (sygen and other gangliosides ) [7, 24, 26-28]. However, none
of these approaches have proven reliable yet and require further study [24, 28]
Neuroregenerative strategies focus on increasing the latent healing abilities of SCI,
either by increasing axon growth or remyelination. The white matter in the CNS is known
to inhibit axon growth, so many strategies involve counteracting those effects. An enzyme
can be used to break down the glycosaminoglycans found in white matter which are
known to inhibit axon growth. Another tactic is to use an antibody to block the activity of
IN-1, an inhibitory protein in oligodendrocyte myelin called Nogo [29, 30]. To increase
remyelination, cellular transplants of peripheral olfactory ensheathing cells, human
mesenchymal stem cells, and oligodendrocyte precursor cells have been used in clinical
spinal cord injury. In vivo studies have shown promising results when adding growth
factors to the injury site, though nothing has been approved for clinal studies [29].
Biomaterials are a promising avenue, however there is only one strategy that has
reached clinical study [9]. A more thorough explanation of current biomaterial approaches
will be given later in the chapter, however it should be stated biomaterials are often
incorporated into neuroregenerative strategies, combining cellular transplant and/or GF
delivery [28, 31, 32].
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As things currently, stand there is no gold standard for treating SCI. The goal of
this thesis is to design a biomaterial system that would combine what we know about
effective SCI treatments with scaffolding techniques known to encourage peripheral nerve
injury repair.
Nervous System Physiology
The nervous system is categorized into two
systems; the central nervous system (CNS) and
the peripheral nervous system (PNS). The CNS
consists of the brain and spinal cord, while the
PNS consists of all nerves that extend from the
spinal cord. Motor neurons are typically used to
show the basic components of a nerve cell
(Figure 1-1). Neurons can vary, but generally
there is a cell body, with the neuron’s nucleus,
dendrites, and a myelinated axon. Axons can be

Figure 1-1 Diagram of a Motor Neuron
from[4], Histology a text and atlas, reused

myelinated by Schwann cells (PNS), or with with permission from Wolters Kluwer
Health Inc.

oligodendrocytes (OLs, in the CNS), and can vary in the thickness of the myelin
sheath[33]. The cell bodies of neurons are in the gray matter of the spinal cord, while the
axons and supporting cells, aka glial cells, are in the white matter [33]. Motor neuron cell
bodies are in the ventral horn of spinal cord and extend to their target muscles, starting
as large bundles of multiple axons that then branch off to connect to closer targets while
the main bundle continues to further targets (Figure 1-2) [33]. Sensory neuron cell bodies
are in the dorsal root ganglia near the spinal cord and extend in both directions, towards
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Figure 1-2 Spinal Cord Physiology
From Ross’ Histology: A Text and Atlas (2011)[4]. Shows a cross-section of a spinal cord, with the locations of
motor and sensory neurons’ cell bodies and axons. Further shows a cross-section of a spinal nerve with
epineurium, perineurium, and endoneurium surrounding individual axons. Three types of nerve axons are
shown, as well: somatic motor neuron, with striated muscle as its target; autonomic unmyelinated neuron with
intestines as its target; and a somatic sensory neuron with a Pacinian corpuscle in skin as its target. Figure is
reused with permission from Wolters Kluwer Health Inc.

the dorsal horn and up to the brainstem via the white matter, as well as towards distal
sensory organs (Figure 1-2) [33]. Interneurons exist in the CNS and form a network of
communication between sensory and motor neurons [4]. Often the central and peripheral
nervous systems are considered as separate systems; usually only one is discussed in
detail for research. They are however very similar and detailed description of both are
necessary for a complete understanding, particularly considering that many peripheral
nerve tissue engineering strategies are applied to SCI.
Central Nervous System
The following is summarized from Ross Histology: A Text and Atlas (6th edition,
2011), with any other references cited normally.
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As previously mentioned, the CNS comprises of the brain and spinal cord. The
spinal cord is continuous with brain stem and is shaped like a flattened cylinder. The
exterior white matter consists of myelinated axons. The internal gray matter is “butterfly”
shaped and consists of neuronal cell bodies, dendrites, and glial cells. The CNS glia
include OLs, astrocytes, microglia, and ependymal cells. OLs serve a similar purpose to
Schwann cells, in that they wrap around axons to form myelin sheaths, though they
produce different myelin proteins and myelinate multiple axons at a time. One key
difference between OLs and Schwann cells is the presence of an inhibitory protein named
Nogo [7, 30, 33] . Astrocytes are the main player in the blood brain barrier, extending
processes to vasculature and to neurons to monitor fluid and particle transport between
the two. Astrocytes also are crucial for reinforcing the tight junctions on vascular
endothelial cells to prevent leaking. Further, they play a large role in glial scarring during
SCI. Microglia are phagocytic cells, acting similarly to macrophages. Ependymal cells are
columnal epithelial cells that line liquid reservoirs such as the central canal in the middle
of the spinal cord gray matter and absorb cerebrospinal fluid.
The spinal cord is segmented by two sets of axons that bundle and leave as nerves
on each side of the spine. Those segments are named based on location in relation to
the spine. There are 31 total segments; 8 cervical, 12 thoracic, 5 lumbar, 5 sacral, and 1
coccygeal segment(s). The spinal cord is protected by layers of connective tissue, the
dura mater, arachnoid space, and pia mater, collectively called the meninges. Dura mater
is the exterior layer made of dense connective tissue, which consists of type 1 collagen
and fibroblasts. The dura mater wraps around the spinal cord and brain, continuous from
the vertebrae and skull periosteum. Arteries and veins can reside within the dura mater.
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The arachnoid is a sheet of loose connective tissue laying on the inside of the dura mater
and is named for the strands of tissue between it and the pia mater, which resembles a
web. The strands contain elongated fibroblasts, while the area between the strands
houses the cerebral spinal fluid and vasculature. The pia mater is single layer of loose
connective tissue directly on top of the brain and spinal cord. Any blood vessel entering
nervous tissue will be lined by pia mater to provide a barrier. When axons leave the CNS,
the pia mater and arachnoid merge and surround the axon, creating a blood-nerve barrier.
The blood-brain barrier works similarly but with the added barrier of the astrocytes as an
intermediary between blood vessels and neurons. This ends the summary from Ross’s
Histology a Text and Atlas. [4]
The extracellular matrix (ECM) of the CNS is unique in that it is not mostly collagen,
elastin, or fibronectin. These do exist in the CNS, though are produced by and near to
the basal lamina of blood vessels [34].

The main ECM materials in the CNS are

glycoproteins and proteoglycans [34]. Hyaluronic acid (HA) is a proteoglycan that serves
as a backbone for the ECM, using link proteins to attach other proteoglycans to HA[34].
Heparan-, keratan-, dermatan-, and chondroitin- sulphate proteoglycans are all attached
in this way [34]. Others include: Lecticans, NG2, phosphacan, and small leucine-rich
proteoglycans [34]. Another protein that attaches itself to the network is tenascin[34].
These ECM proteins are made by the neuroglia, especially by OLs and oligodendrocyte
precursor cells (OPCs), and can be concentrated around neuron cell bodies (perineural
networks) or spread out (interstitial) [34]. The ECM can be inhibitory to axonal growth,
however this is instrumental during development and injury as a way to guide proper brain
and spinal cord structure[30, 34].
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The Peripheral Nervous System (PNS)
The PNS is organized as bundles of bundles of nerve fibers (Fig. 1.2, page 5).
Each nerve axon is surrounded by a segmented myelin sheath, Schwann cells, and a
protective guide called the endoneurium. A bundle of these protected axons, called a
fascicle, is surrounded by a perineurium. A bundle of fascicles is surrounded by the
epineurium, the outermost guide to the nerve. [4]
The following is summarized from Topp K.S. and Boyd B.S. [9], with exceptions
cited normally:
Each level of the structure has various cells and ECM components involved.
Schwann cells are surrounded by a basal lamina including: type IV collagen, fibronectin,
laminin, and heparan sulfate proteoglycan.

The endoneurium consists of loosely

connected type I and II collagen oriented longitudinally, as well as fibroblasts, mast cells,
fat cells, macrophages, and endoneurial fluid. The perineurium is comprised of 15 layers
of flat perineurial cells. Perineurial cells are squamous cells with the characteristics of
endothelial cells (such as tight junctions, complete basal lamina, and mechanisms for
transport across the cells) and smooth muscle cells (actin filaments and contractile
function) [10]. In between each perineurial cell layer there are type I and type II collagen
and elastic fibers. These components are arranged obliquely, circumferentially, and
longitudinally to the perineurial cell layers. The innermost perineurial layer contains
laminin and heparan sulfate proteoglycans in addition to the collagen and elastic fibers.
Additionally, the innermost layer serves as a diffusion barrier that aids the blood-nerve
barrier in regulating the endoneurial environment. The epineurium has type I and type
III collagen, elastic fibers, fibroblasts, mast cells, and fat cells. In cases where there are
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multiple fascicles within the epineurium, there is ample interfascicular epineurium that
allows for fascicles to slide independently of one another, as well as avenues for
vascularization within the nerve. The outermost epineurium tissues are connected to the
surrounding fascia to stay in place.

Adipose tissue is present in this fascia as an

additional protective layer for the nerve against compressive forces. Arteries run parallel
to the epineurium exterior, branching into arterioles to run within the interfascicular
epineurium. The arterioles pass through the perineurium, and within the endoneurium
become large-diameter capillaries that run along the nerves with tight junctions to form
the blood-nerve barrier. This ends the summary from Topp K.S [9]
Nerve injury environments
In many ways, the CNS and PNS act similarly during an injury response. However,
the CNS adds a few interesting interactions to the “typical” PNS injury response. For this
section, I will explain the peripheral nerve injury (PNI) response first, and then delve into
the spinal cord injury (SCI) response.
Peripheral Nerve Injury
Seddon [35] defined a rubric for PNI severity consisting of three categories,
neuropraxia, axonotmesis, and neurotmesis. In the most severe case of neurotmesis,
natural wound healing responses are not sufficient to reconnect the nerve. With no
connection, Wallerian degeneration at the distal injury site increases the gap between the
severed ends. This increases the time for functional recovery from a few days to months
and even years. Cases in which peripheral nerves are cut and can be immediately sutured
together, natural peripheral nerve growth is sufficient to return function. After about 6mm,
however, natural growth is no longer sufficient [36]. The current gold standard for large
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PNI is autologous nerve grafts [37]. However, an autologous nerve graft requires donor
site morbidity. As such, a tissue engineering solution is sought to reconnect the damaged
nerve quickly to prevent Wallerian Degeneration and without causing damage to another
site in the patient.
Schwann cells maintain the myelin sheath and protect the axon [38]. In healthy
nerve, Schwann cells are in an “inactive” state, where myelination maintenance is
prioritized [39]. Within 24-48 hours of PNI, the nerve distal to the injury site undergoes
Wallerian degeneration (Figure 1-3); Schwann cells begin breaking down myelin and
macrophages are recruited to clear the debris of the degenerated nerve [39-41]. The
Schwann cells then de-differentiate to a proliferative state. The activated Schwann cells
multiply and align to form bands of Bungner to bridge the PNI gap and start the
regeneration process [39]. Growth cones are formed on the proximal end of the PNI,
which use biomechanical and chemical cues to determine which direction the axon will

Figure 1-3 Wallerian Degeneration and Nerve regeneration.
Illustration of a nerve injury and following regeneration process, from Faroni et al(2015) [1]. Reused with
permission from Elsevier.
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grow [42, 43]. Depending on the amount of damage, the nerve may regenerate fast
enough to connect with the distal nerve. Nerve regeneration rate is generally considered
to be 1mm/day, though can vary between 0.5-9mm/day depending on the tissue/species
type, measuring system, and distance of the injury from the cell body [40, 41]. If the
proximal end cannot reach the distal end within 24 hours, then the entire distal nerve may
begin to degenerate [41]. Within 5-8 weeks, the nerve degeneration process will be
completed, though Schwann cells and the endoneurial sheath will remain [41]. Mast cells
and fibroblasts are also active during this process, though they take up a more traditional
wound response of enabling macrophages and producing scar tissue, respectively [41].
The PNI severity rubric described by Seddon [35] considers Wallerian degeneration when
categorizing PNI. Neuropraxia is axonal injury with no Wallerian degeneration.
Axonotmesis is axonal and endoneurial or perineurial injury that results in Wallerian
degeneration, though the epineurium is still intact. Lastly, neurotmesis is a complete sever
of the nerve through all structures [35, 44].
In addition to the cellular activity described above, various changes occur in gene
expression and growth factor (GF) release. Neurotrophic factors such as: Nerve Growth
Factor (NGF), Brain Derived Neurotrophic Factor (BDNF), Glial-cell-line-derived
Neurotrophic Factor, neurotrophin 3, basic Fibroblast Growth Factor (bFGF), and
Transforming Growth Factor – β (TGF-β) are all upregulated after PNI [39-41]. Antineurotrophic factors such as histone deacetylase 5 and 6 are upregulated as well[40].
Transcription factors, too: Growth-associated protein 43, JAK/STAT, and cytoskeletonassociated protein 23 are all upregulated [39, 40]. Though these are all upregulated, this
alone is a bit deceiving, as some of these upregulated factors work opposite one another.
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As an example, BDNF promotes remyelination, however bFGF inhibits remyelination and
promotes Schwann cell proliferation [39]. Several other factors also have the trade-off
between Schwann cell proliferation and remyelination [39]. This suggests that when a
factor/signal is present is very important for optimal nerve growth and regeneration.

Spinal Cord Injury
SCI is a multiphase event [7, 9, 45]. The primary phase is the initial incident that
caused damage to the spinal cord, which can either be blunt, crushing damage, or a sharp
laceration, transection, or stabbing damage [7, 34]. If the damage was sharp such that
the dura mater was injured, then more blood macrophages and fibroblasts will have
access to the site[34]. If the damage was crushing such that the dura mater remains
intact, fewer circulating macrophages and fibroblasts will get through, leaving the fluid
filled gap where the damaged nerve was for the neuroglia to handle [34]. The secondary
phase is how the spinal cord reacts for the next several months to years and can enlarge
the area of injury, a phenomenon known as axonal dieback [7, 31, 46]. Secondary SCI is
further split into acute, subacute, and chronic phases [7, 9, 45]. These phases are not
fully defined and can be considered a sliding scale of time depending on the individual [7,
30].
The acute phase starts immediately after injury and lasts up to 48 hours [7] and is
characterized by an influx of immune cells and a hyperactive inflammatory response [46].
Neuroglia and local macrophages release cytokines to increase migration of immune cells
and to increase proliferation of phagocytic cells [46]. If the dura mater is damaged, there
is a larger immune response from invading macrophages [34, 46]. There is also a large
loss of OLs, due to the immune response[46]. Loss of OLs are considered a major
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contributor to neural degeneration during this phase, along with ion imbalance and
edema, and excitotoxicity from overstimulated glutamate receptors leading to tissue
necrosis [46]. In addition to inflammatory cytokines, various GFs become upregulated.
Acidic fibroblast growth factor (aFGF) and bFGF are both released about 1 hour after
injury [47]. Though the FGFs are known to affect many cells in many ways, in spinal cord
aFGF induces angiogenesis, reactive astrocytes, M2 pro-healing macrophage
phenotype, and production of NGF and BDNF [46, 47]. bFGF reduces tissue necrosis,
increases astrocyte proliferation, protects OLs, and increases OPC proliferation [47].
Neurotrophic factor-3 and transforming growth factor-β are detected as well. NGF, BDNF,
and neurotrophic factor-3 serve to guide axonal growth and are all noticeable at around
six hours after SCI, though NGF and neurotrophic factor- 3 dissipate quickly[46]. Another
important note is that Wallerian degeneration as it is described for peripheral nerve injury
is the same for distal segments in SCI [29, 30]. Treatment strategies in the acute phase
generally attempt to reduce inflammation, neuronal cell death, and tissue necrosis [7].
Subacute phase is generally defined to last up to 2 weeks after SCI [7]. This phase
is characterized by phagocytic activity, increased number of reactive astrocytes, and glial
scar formation [7]. If the SCI was sharp, breaking the dura mater, there will be more
invading fibroblasts to make a fibrous scar in addition to the glial scar [34]. Reactive
astrocytes are the main cellular component of the glial scar, known to swell and extend
to make mesh with other reactive astrocytes, [7, 30, 34, 46]. Reactive astrocytes produce
sulfated proteoglycans, primarily chondroitin sulfate proteoglycan, and work to reinstate
the blood brain barrier [7, 34, 46]. OL and OPCs also start contributing to the glial scar by
proliferating and producing inhibitory ECM and the protein NG-2 [29]. Three to four days
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after SCI, macrophage infiltration is at its peak [46]. Within the glial scar, macrophages
and glial ECM mediate neuronal “dieback” and a dystrophic growth state [30]. Dystrophic
growth state describes a cycle of the neuronal growth cone constantly growing and
retracting from inhibitory signals, usually provided by macrophages, astrocytes, and CNS
myelin proteins [7, 30]. Though it may seem tempting to stop glial scar formation by
removing astrocytes from the site, the glial scar is vital for protecting the area around the
SCI, re-establishing the blood-brain-barrier, and regulating SCI homeostasis [7, 46, 48].
Growth factors released during the acute phase are still around for the subacute phase.
aFGF is typically seen at 1 hour after treatment, peaks at 5-7 days and remains elevated
for 14-21 days [46]. bFGF is also seen at 1hour after injury, but peaks at 2-3 days and
lingers until 14-21 days when it reaches normal levels again [46]. BDNF release, which
is activated by aFGF, is detected after 6 hours from SCI, builds up for 6 weeks, then
diminishes after 12 weeks [46, 47]. Note that BDNF is known to help axonal growth [29,
46].

Treatment strategies used in the subacute phase tend toward containing and

reducing the inflammatory response, to attenuate the dystrophic growth state [7].
The chronic phase is generally agreed to begin after 6 months post SCI [30]. It is
characterized by the completion of the glial scar, a fluid filled cavity where the nerve was,
and a continuation of the dystrophic growth state [7, 30]. The treatment strategy here is
to enhance neural regeneration and remyelination in hopes of overcoming the inhibitory
effects of the glial scar [7]. Additionally, patients will often work on strength exercises to
curb muscle atrophy [30].
Typically, when one is hospitalized for SCI, the treatment starts with immobilization
of the spinal cord for transport followed by stabilization breathing, heart rate, and
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preventing issues such as blood clots and shock [9, 49]. Then the patient is transported
to an intensive care unit or specialized SCI center for treatments mentioned earlier in the
Current Clinical Treatments and Pre-Clinical Trials section [49]. Depending on how fast
the patient is stabilized and can schedule a surgery, it is feasible to use a surgical
intervention within the acute and subacute phases, after the initial inflammation influx, but
before the glial scar has fully formed. In this case, a spatiotemporal combination of two
GFs seems promising: bFGF to immediately provide oligodendrocyte protection and
reduction of tissue necrosis; and BDNF released later to guide axonal growth through the
glial scar. The precise timing to match the injury environment would need to be: bFGF
immediately released with a peak around 1-2 days and lingering for 14 days; BDNF
released by day 3-4, gradually increasing until a peak at 6 weeks. Though less ideal, this
could also be useful at later stages of SCI. Doing so would require removal of the glial
scar to implant the system; this would effectively re-open the initial SCI and start the acute
phase over again.
Current Tissue Engineering Approaches and Technologies
There are many promising tissue engineering solutions being explored for the
acute and subacute phases which combine the well-researched strategies from
peripheral nerve injury repair and clinical SCI treatment [50, 51]. It is well established
that CNS nerve reacts similarly to peripheral nerve given the proper conditions [52], that
PNI strategies can be adapted for use in the CNS [51], and are worth outlining before
delving into how CNS strategies improve upon them.
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Peripheral Nerve Injury (PNI)
The epineurium inspires the
conduit

structure

for

tissue

engineering solutions. Considering
the natural structure and function of
the nerve, it has been said the ideal
nerve tissue engineering construct
are: porosity, biodegradability, ability
Figure 1-4 Nerve Guide Conduit Modification

for diffusion or release of GFs, the Schematic of different nerve guide conduit modifications,
ability

to

include

support

commonly studied for peripheral nerve repair from de

and Ruiter (2009) [2, 3]. Reused with permission from The
Journal of Neurosurgery and Elsevier.

maintain support cells, aligned structure and intraluminal channel, and finally to allow
electric signals to propagate [36, 37, 53] (Figure 1-4). Though these characteristics are
all valid goals for nerve conduits, previous research in our lab has found success with a
combination of aligned substratum structure and controlled release of GFs [3].
In addition to the structure, the composition of the peripheral nerve is also
inspiration for scaffold material.

Native materials such as collagen type I, laminin,

fibronectin, and proteoglycans are often used in nerve conduits [37, 53, 54]. Synthetic
polymers such as poly (glycolic acid), poly(lactic acid), poly(lactic-co-glycolic) acid
(PLGA),

poly(caprolactone) , and silicone, have been used due to their tunable

biodegradation characteristics, ease of processing, availability, and FDA approval [53,
55-57]. However, these materials have come under scrutiny due to acidic degradation
waste products and lack of permeability [53, 58] As such, other non-native natural
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materials, such as chitosan, gelatin, and alginate have become popular and have
received positive results [36, 37, 53, 59-64]
A further consideration is the microstructure of the ECM, and what methods can
mimic it. Electrospinning is method that produces fibrous mats of nanofibers from a
polymer or natural material solution [3, 65, 66]. The fibers can be aligned or unaligned for
controlled topographical cues [3, 67]. This method provides a similar fibrous material to
that of ECM and the aligned collagen and elastin of the epi-, peri-, and endo-neuriums [4,
36, 68-71] and has seen great use for neural tissue engineering [3, 53, 65, 67, 72-74],
among other tissue engineering applications [75-78]. Coaxial spinning is an alternate
electrospinning method that uses two solutions and outputs fibers with an internal core
and outer shell of the two solutions [79, 80]. Another conduit design strategy is to mimic
the empty endoneurium tube like structure that occurs after Wallerian degeneration has
occurred. This can be done by either creating a porous material. A randomly porous
material can be made by crosslinking the scaffold material with polystyrene microspheres
mixed in, then dissolving the microspheres to leave pores in the scaffold; a process called
particulate leaching [63] and longitudinally porous materials can be made by flash
freezing chitosan in liquid nitrogen [81].
Many GFs have been identified as beneficial to peripheral nerve growth. For
convenience, Table 1-1 summarizes the GFs, their abbreviations, and a list of the
references. These GFs are delivered in different ways, most which can be categorized
as microsphere (MS) release, hydrogel release, cell excretion, or scaffold degradation
release.
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Table 1-1 Growth factors known to help PNI regeneration
Growth Factor
Neural Growth Factor*
Brain Derived Neurotrophic Factor*
Epidermal Growth Factor
Neurotrophic Factor 3*
Neurotrophic Factor 4/5*
Ciliary Neurotrophic Factor*
Glial Cell-Line Derived Growth factor*
Fibroblast Growth Factor-1*
Fibroblast Growth Factor-2*
Platelet Derived Growth Factor*
Glial Growth Factor*
Vascular Endothelial Growth Factor*
Leukemia Inhibitory Factor*
Insulin-like Growth Factor*
Transforming Growth Factor - β
Tumor Necrosis Factor*

Abbreviation
NGF
BDNF
EGF
NT-3
NT-4/5
CNTF
GDNF
FGF-1
FGF-2
PDGF
GGF
VEGF
LIF
IGF-1
TGF-β
TNF-α

Reference
[3, 54, 62, 82-86]
[37, 82]
[59, 87]
[37, 82, 88]
[82]
[82, 89]
[82, 90]
[37, 82, 91]
[37, 82, 92]
[82]
[57, 79, 82]
[37, 82, 93]†
[82]
[37, 82]
[64]
[82]

*Growth factor was also in a table in a review [82], see original table for more sources.
†Reference indicates negative effect on nerve regeneration.

MS have been used in conduits for nerve regeneration before [3, 59, 60, 63, 65,
84, 92, 94-97]. PLGA has been seen to have GF release up to 55 to 84 days depending
on MS configuration [3, 59, 65]. In contrast, chitosan microspheres were seen to have
about 7 days of GF release [59]. Both materials focus on having GFs around as long as
possible. However, GFs have a more complex spatiotemporal release profile. As an
example, bFGF is known to enhance nerve regeneration [37, 82, 87, 92], but bFGF is
only upregulated from day 0 to day 18 after PNI with a peak at day 7 [39, 98]. bFGF is
known to suppress myelination of axons and support axonal growth; though this may be
ideal at the beginning of the nerve injury, having prolonged bFGF exposure can lead to
thinner myelin sheaths and a lack of resting Schwann cells [39, 68]. BDNF which is also
known for enhancing nerve regeneration [37, 58, 82], has an opposing effect to bFGF.

19

BDNF promotes Schwann cell differentiation to the myelination state [39], and is
expressed from day 3 after PNI until approximately day 42 with a peak at day 28 [39, 99].
Just this one example emphasizes the need for precise spatiotemporal control of GF
release and, coincidentally, the timing is mirrored in SCI.
Spinal Cord Injury (SCI)
Conduits used in PNI are a popular strategy for use in SCI, especially when
combined with aligned substrata and/or GFs [48, 50, 67, 100, 101]. Hydrogels are also a
popular strategy [50, 100, 102-105]. Conduits are typically used for sharp injuries that
either break the dura mater or sever the spinal cord completely, while hydrogels are
typically injected after blunt trauma. The key factors to consider for SCI are similar to PNI,
but with a few differences. Effective SCI should: reactivate neurons’ intrinsic growth
capacity, establish a permissive area for neuronal growth, and modulate the inflammatory
response [48, 67, 106], in addition to what was listed for PNI [36, 50], particularly to form
a path for neuronal growth [29, 48, 67].
Reactivating the intrinsic growth capacity is the most difficult and is often ignored.
Anderson et al 2018 accomplished this with a pre-treatment of ciliary neurotrophic factor,
osteopontin, and insulin-like growth factor 1 two weeks prior to SCI in their animal model
[48]. Another way this can be achieved is by damaging peripheral nerves distal to the
injured spinal cord in order to condition the SCI lesion [7]. Conditioning can also be
achieved by inducing inflammation in the distal DRG or vitreous humor in the eye, or by
electrically stimulating the sciatic nerve [7]. More research is needed to fully understand
how to condition the SCI for increased intrinsic growth capacity.
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To establish a permissive area for neuronal growth, strategies typically attempt to
combat the inhibitory glial scar. As a reminder, clinical homologues are to use the enzyme
ABChase to degrade prohibitory regions in chondroitin sulfate proteoglycans or using
antibodies against the Nogo protein in oligodendrocyte myelin [7]. Tissue engineering has
found success by using GFs to encourage neuronal growth past the scar tissue [48],
though a single GF is usually not enough [29]. Many combinations try to have one GF
that protects OLs and OPCs such as bFGF, ciliary neurotrophic factor, and insulin-like
growth factor, with a second GF that guides and encourages axonal growth such as
BDNF, NGF, neurotrophic factor-3, glial derived neurotrophic factor [7, 29]. Though in
some studies two axonal growth GFs, such as BDNF and neurotrophic factor-3, worked
well together to overcome the inhibitory effects of the glial scar [29]. Additionally, many
strategies implant cells to supplement to the native OLs and their GF secretion abilities.
Such cells include olfactory ensheathing cells, mesenchymal stem cells, induced
pluripotent stem cells, Schwann cells, neural progenitor cells, and embryonic stems cells
[7, 29]
Lastly, creating a guiding path for neuronal regeneration can be achieved in many
ways including using scaffolds with aligned channels or aligned fibers, as used for PNI
and described earlier [67, 100]. Materials used for such aligned fibers in SCI include
those used in PNI such as collagen and alginate, but also include hyaluronic acid (HA).
A brief reminder: spinal cord ECM consists of primarily of HA with sulfated proteoglycans
and other proteins, but also has a very aligned structure with the axons and myelin
sheaths[34]. HA can be methacrylated (MeHA) and electrospun into aligned nanofibers
and have been used for PNI to show increased neurite outgrowth [65].
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Motivation for thesis
Spatiotemporal release has gained popularity in other tissues, such as bone and
cartilage [107-111], and recently has become a necessity for SCI [31, 48]. Methods such
as tunable hydrogels [112-114] seem promising but take trial and error to find the correct
formulation of the hydrogel to meet the desired timeframe. Cells can be programmed or
transfected with genes to produce desired GFs, and usually with an on/off switch included
[7, 25, 29, 105, 115-117]. These cellular methods can come under fire from immune
response concerns, and lentiviral vector transfection is often blocked by regulatory issues.
Core-shell droplets have been used [118] with release times of at least 30 days, and rates
that are different for each of the two growth factors, but they start releasing at the same
time. Additionally, a drawback is that a large burst effect of 30% growth factor release is
seen within 1-2 days of the initial implant [118]. However, these two drawbacks can be
remedied.
GF sequestration is a naturally occurring phenomenon where heparin binding sites
in the extracellular matrix hold onto free floating GFs. This is useful because it prevents
the GF from being degraded while still being available to bind and signal cells. In GF
delivery, heparin binding has been used in cardiac tissue [119] and nerve tissue [83, 86,
97, 120] as a way to prolong GF delivery duration. Heparin is known to sequester many
GFs, including BDNF and bFGF [121], and more recently has seen use in SCI [122].
Additionally, heparin can be modified to bind with methacrylate groups [123], and thus
can be combined with MeHA.
Our lab has previously developed conduits and electrospun fibers made from
MeHA and including PLGA microspheres for GF release [3, 65]. These microsphere
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containing nanofibers can be improved upon by 1) using multiple microspheres for
differing release time-points and 2) conjugating heparin to MeHA to both prevent a burst
effect and keep the GFs active longer, so as to mimic natural release and availability in
the acute and subacute SCI environment.

This one-two approach will allow for

spatiotemporal control of GF release time and duration in an eventual nerve guide conduit
for SCI.
Objective and Specific Aims
SCI is a lifelong condition with no gold standard of care; currently affecting 291,000
people in the United States, with an estimated 17,730 new cases annually [8]. The current
clinical treatments for SCI focus on reducing inflammation and preventing more damage
post injury, with no clear best choice for care [9]. There are many tissue engineering
strategies being explored, primarily conduits nerve guides and injectable hydrogels [48,
53]. Most consider the two strategies: a) to deliver growth factors to enhance axonal
growth and remyelination, and b) to influence the inflammatory milieu of the area
surrounding the SCI to reduce cell death and tissue necrosis.
I propose and develop a precise spatiotemporal GF release system that will
provide two growth factors at the times and durations as seen following SCI. Though
there are many GFs at play in SCI, this thesis focuses on bFGF and BDNF. bFGF is
upregulated 1 hour after SCI, has peak values at day 3, and then has low levels from day
14-21

[46,

47].

bFGF’s

role

in

SCI

includes

protecting

OLs,

inducing

proliferation/migration of OPCs [47], and reducing tissue necrosis [7]. BDNF is
upregulated 6 hours after SCI, lasts 6 to 12 weeks, and guides axonal growth [29, 46].
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I use two different types of microspheres to control the release time-point of bFGF
and BDNF, and heparin modified hyaluronic acid (HepHA) nanofibrous scaffolds are used
to maintain GF bioactivity for long term availability. Poly-lactic-co-glycolic acid
microspheres (PLGA-MS) and gelatin microspheres (GMS) are electrospun with HepHA
nanofibers, such that after the GFs are released at their respective timelines, the heparin
can sequester free floating GFs and prevent GF degradation. PLGA-MS are hydrolytically
degraded and will be used to deliver bFGF immediately after application.

Gelatin

microspheres (GMS) are enzymatically degraded by collagenase [124]. Using the body’s
natural injury response and immune cell invasion, GMS is intended to provide a delayed
release of BDNF as M1 macrophages become prominent and produce collagenase,
increasingly so from the time of injury until 5-7 days after injury [31] .
The objective of this research is to determine if a spatiotemporal release of
bFGF and BDNF will produce increased spinal cord regeneration as compared to
nanofibers alone, bFGF alone, or BNDF alone. I will be testing the hypotheses: An
implantable spatiotemporal system (STS) that releases bFGF and BDNF for time periods
that mimic natural nerve injury response will provide enhanced neurite reconnection and
improved oligodendrocyte survival in an organotypic spinal cord lesion model as
compared to the model without the STS. I develop the STS and test these hypotheses
via three specific aims.
.
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Specific Aim 1: Chapter 2 – Heparin-hyaluronic acid nanofibers for growth factor
sequestration in spinal cord repair.
Soluble GFs will be phagocytosed shortly after release unless they are bound.
Heparin is known to bind to both bFGF and BDNF while keeping their active sites
available [121]. I have altered heparin in two ways, methacrylation and thiolation [123],
such that it can be photocrosslinked to an established MeHA aligned nanofibrous scaffold.
We expected that at least one form of modified heparin, electrospun with MeHA, would
successfully sequester bFGF and NGF in solution. We hypothesized that the sequestered
GFs would increase L929 fibroblast proliferation and neurite extension from chick
neurons. We not only showed that methacrylated heparin with HA (HepHA) fibers will
sequester GFs if treated ahead of the cell experiment, but also that the fibers would
actively sequester GFs over the course of the three-day neuron experiment. From this
aim, we moved forward with methacrylated heparin for our HepHA nanofibers in Aim 3.

Specific Aim 2: Chapter 3 – Macrophage mediated growth factor release from gelatin
microspheres for spinal cord injury
Immediate release of GFs has been done extensively. In this aim, we use GMS
that were previously used for bone regeneration and mediated GF release with the
respective immune response [124]. We applied these GMS to SCI, which also undergoes
a large immune response during the healing process [7, 9, 31, 45].
We produced GMS, characterized the crosslinking percentage, loaded GMS with
NGF with 99.8% efficiency, and determined an NGF release rate in the presence of
collagenase. We also tested the GMS electrospun with MeHA fibers (GMSF).

M1
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macrophage conditioned media (M1CM) was used to imitate a macrophage invasion,
added for the duration of the three-day chick neuron experiment. M0 macrophage
conditioned media was used as a control group. We hypothesized that neurons cultured
with GMSF+NGF and M1 conditioned media would have longer neurites than neurons
grown with empty GMSF or on MeHA, regardless of the media conditions.
We found that GMS in general had a positive impact on neurite outgrowth, possibly
due to the affinity binding potential of gelatin. GMSF+NGF had increased neurites in all
serum conditions but were longest in M1CM. Further we found that GMSF in M1CM also
had longer neurites, indicating that the degraded gelatin had a positive effect on the
neurites, potentially due to interactions with cytokines in M1CM. Our ELISA confirms that
GMS degradation and GF release is trigged by collagenase, and our neurite experiment
confirms functional GFs could be released from electrospun fibers. We moved forward to
combine GMS with PLGA-MS and HepHA, to be tested in an organotypic spinal cord
model in Aim 3.

Specific Aim 3: Chapter 4 – Spatiotemporal growth factor system evaluated in a
biomaterial-based organotypic spinal cord injury model
In aims 1 and 2, we developed HepHA to sequester released growth factors and
confirmed a delayed release of GFs from GMS. In this Chapter, we combined PLGA-MS
that were previously established in the lab [3, 65] and the GMS from chapter 3 within the
HepHA electrospinning solution from chapter 2 to create the spatiotemporal system
(STS). Further, we developed a 3D printed insert for an organotypic spinal cord (OSC)
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model to reduce the costs and time of evaluating the STS in an in vivo spinal cord study,
while as maintaining a level of control that can be achieved in vitro with single cell studies.
Several iterations were performed to optimize the OSC insert design, culture
conditions, and processing procedures. Ultimately, we were able to culture spinal cord
explants for one week, with an addition of M1 macrophage conditioned media after three
days to simulate immune cell invasion. We hypothesized that OSCs grown with the STS
would have increased neurite reconnection and greater oligodendrocyte presence as
compared to OSCs grown with one or none of the GFs.
Though individual neurites were out of our grasp due to the thickness of the tissue
samples, we did define the post injury gap size and quantify the percent gap recovery.
We found that the STS tended to have the highest percent gap recovery at 87%, though
not significantly so. Additionally, we visualized Olig2+ OLs and quantified OL cell number
per injury gap and normalized those values by the gap area (per mm2) to obtain OL cell
density, providing two metrics to evaluate OL presence within the injury gap. STS had
the highest average oligodendrocyte cell number per gap, though also not significantly
so. HepHA had the highest OL density, though not significantly so.
In this chapter, and thesis, we developed an STS to deliver bFGF and BDNF at
times that mimic the natural SCI environment and has shown itself to be a promising
strategy for SCI regeneration. HepHA, without GFs also showed promising results,
indicating that other GFs or cytokines available to SCI may be useful as well. More
research is needed to confirm these trends, but the biomaterial focused OSC will be of
great help to perform such research with reduced costs of time and life, as well as by
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providing a model that can grow complex tissue systems in a more controlled, in vitro
setting.
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CHAPTER 2: HEPARIN-HYALURONIC ACID NANOFIBERS FOR GROWTH FACTOR
SEQUESTRATION IN SPINAL CORD INJURY REPAIR
This paper was published by John Wiley and Sons in the Journal of Biomedical
Materials Research Part A, reused for a dissertation with permission from Wiley. As such,
abbreviation definitions may be repeated, though not bolded, in this section. The
supplemental figure can be found in Appendix A.
Introduction
Spinal Cord Injury (SCI) currently affects 291,000 people in the United States, with
an estimated 17,730 new cases annually [125]. SCI has devastating effects on affected
persons’ quality of life, and could cost anywhere from $2-4 million over a person’s lifetime
[11, 16, 17, 19, 20].

Though not clinically available, tissue engineering has found

promising strategies for SCI by implanting or injecting biomaterials including growth
factors (GFs) to encourage neuronal growth past the glial scar tissue [48]; however, a
single GF is not sufficient [29]. Studies that include multiple GFs typically include one GF
or cytokine that protects oligodendrocytes (OLs) and oligodendrocyte precursor cells
(OPCs) such as basic fibroblast growth factor (bFGF), ciliary neurotrophic factor, and
insulin-like growth factor, with a second GF that guides and encourages axonal growth
such as brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), and
neurotrophic factor-3 (NT-3)[7, 29]. Though in some studies two axonal growth GFs, such
as BDNF and NT-3, worked well together to overcome some of the inhibitory effects of
the glial scar [29].
Growth factors can be delivered using bolus injection, microspheres, scaffold
encapsulation, and cellular or lentiviral delivery, however many of these have a large burst
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effect of 30% GF release seen within 1-2 days of the initial implant [118]. Due to GF
degradation and diffusion in vivo, this can reduce the effectiveness of the treatment,
require increased doses or treatments, or even introduce side effects [126, 127]. These
issues are counteracted in native tissue with binding sites, such as seen with heparin, in
the extracellular matrix (ECM) that sequester GFs [123]. Heparin is known to bind to
many growth factors, including Fibroblast Growth Factors (FGFs) and neurotrophic
factors [121]. Many tissue engineering studies have incorporated heparin into their
scaffolds for increased or spatiotemporal growth factor release [83, 90, 112, 119, 123,
128-131], and a few have combined heparin with hyaluronic acid (HA), an ECM
component in the central nervous system [132-135]. Lee et al in 2003, found that heparin
and NGF inside of a peripheral nerve guide conduit increased nerve regeneration as
compared to NGF alone and conduit alone [83].
Previous studies have shown the ability to modify heparin in two ways, by
methacrylation and by thiolation [123], which can then be conjugated onto other polymers.
Our lab has previously shown the ability to methacrylate hyaluronic acid (MeHA), and
electrospin it into aligned nanofibrous mats for directed neurite outgrowth [3, 65, 73, 136].
Our lab has previously released GFs via poly(lactic-co-glycolic acid) microspheres
incorporated into the MeHA electrospinning solution, such that the microspheres were
imbedded within the aligned nanofibers [65]. Microspheres+GF groups showed increased
neurite outgrowth from chick dorsal root ganglia (DRG) compared to groups without GFs.
We propose that this system could be further improved by adding heparin domains to
MeHA in order to sequester released growth factors for prolonged nerve regeneration.
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The objective of this paper is to investigate the effectiveness of combining
methacrylated heparin (HepMA) or thiolated heparin (HepSH) with MeHA (HepMAHA and
HepSHHA) scaffolds to sequester functional GFs relevant to SCI. We evaluated the
methacrylation and thiolation of heparin through NMR spectroscopy. We tested MeHA,
HepMAHA, and HepSHHA in in vitro experiments using fibroblast proliferation to evaluate
bFGF functionality and DRG neurite length to evaluate NGF functionality. All fiber types
were tested as loaded and unloaded; where loaded fibers are incubated with GFs prior to
cell culture, in order to allow heparin to sequester the GFs. We hypothesized that heparin
scaffolds will successfully sequester functional growth factors, specifically bFGF and
NGF, leading to improved cell behavior towards tissue engineering strategies for SCI
repair.
Methods and Materials
Unless specified otherwise, materials were obtained from Thermofisher Scientific
(Waltham, MA).
MeHA synthesis
MeHA was synthesized as previously described [65, 137]. Briefly, methacrylic
anhydride in 20 molar excess was added dropwise to a solution of 1% w/v HA in deionized
water over ice at a pH of 8.0, dialyzed, lyophilized and stored at -20C until use.

Heparin Modification
Two methods were used to modify heparin sodium salt (AAA1619803):
methacrylated heparin (HepMA) and thiolated Heparin (HepSH) [123]. Both were
photocrosslinked to MeHA using Irgacure 2959 and 365nm UV light. HepMA was made
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by dissolving 1% heparin in PBS, then adding 10 molar excess of methacrylic anhydride
dropwise, adjusting pH to 8.0. HepSH was made by dissolving 1% heparin in PBS and
then

reacting

at

pH

6.5

with

1-ethyl-3-(3-dimethylaminopropryl)

carbodiimide

hydrochloride, 1-hydroxybenzotriazole hydrate, and cysteamine, in 3.5x, 2.5x, and 3x
molar excess of carboxylic groups in heparin, respectively. Both products were dialyzed
against DI water and lyophilized for storage. For NMR spectra, samples were dissolved
3% w/v in deuterium oxide and then analyzed using a 400 Hz Mercury Proton NMR.
Electrospun fiber preparation
MeHA electrospinning solution was made from 2% w/v MeHA, 3% w/v
polyethylene oxide, and 0.05% Irgacure 2595 photocrosslinker in DI H2O as previously
described [65]. After electrospinning for 30 minutes, the resulting matrix of MeHA fibers
were crosslinked using a 365 nm wavelength UV light. HepMAHA or HepSHHA
electrospinning solutions were made of 0.5% hepMA or hepSH, 1.5% MeHA, 3%
polyethylene oxide, and 0.05% I2959 in DI water. Otherwise, the method is the same as
electrospinning MeHA. From here on, fibers with hepMA will be called hepMAHA, while
fibers made with hepSH will be called hepSHHA. All fiber types were prepared by gold
sputter under argon vacuum and imaged with a JSM 6510LV tungsten scanning electron
microscope (SEM).
Fiber Alignment and Diameter
SEM images of each fiber type were analyzed using the DiameterJ plugin for
ImageJ. This process has been previously described [138]. The SEM image was
binarized and manually edited using ImageJ to fix any fibers that were still partially omitted
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in the segmented image. This was done by overlaying the segmented image on the
original image and using ImageJ’s fill tool to bring the omitted fiber into the foreground.
Then, the final segmented image was processed by DiameterJ 1-018 to measure the fiber
diameter and alignment.

Five SEM images were analyzed from a single batch of

electrospun fibers for each fiber type; the measurements from each of those SEM images’
respective segmented images were averaged to yield a final measurement for that fiber
type. OrientationJ produces a histogram with the frequency of fibers at a particular angle,
ranging from -89 to 90, for all segmented images. D’Amato et al, described aligned fibers
to be where a majority of fibers are within 15 degrees of the average fiber alignment [67].
As DiameterJ supplied circular data, we considered every possible band of 30 degrees,
found the band with the highest number of fibers, then calculated the percentage of fibers
in that band as compared to total fibers. This was done for each of the five SEM images,
averaged, and reported as the percent alignment.
bFGF Sequestration
HepMAHA, HepSHHA, and MeHA fibers were hydrated for at least 24 hours in
PBS, with one change during the 24 hours. A total of 12 groups were tested: the three
fiber types with and without bFGF loading, as well as with and without bFGF
supplemented growth media. To load fibers, 1ml of 100ng/ml bFGF was added for 2
hours at 37°C, and the fibers were rinsed with PBS 7 times, including an overnight rinse.
L929 growth media consisted of Dulbecco’s Modified Eagle Medium (DMEM) with 10%
fetal bovine serum and 1% penicillin/streptomycin. Supplemented growth media also
included 10ng/ml bFGF. L929 fibroblasts, 25k/well, were allowed to attach for two hours
before the fibers were transferred to fresh wells for proliferation experiments. This was
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done in order to remove cells that attached to the bottom of the well. The moment of
transfer was considered the zero timepoint for the experiment. Cell proliferation was
measured using alamarBlue assay as previously described; as cells proliferate the
alamarBlue reagent becomes visibly reduced, optical densities can be measured, and a
percentage of reduction can be obtained when compared to alamarBlue solution that was
not exposed to cells. [73]. At 20 and 44 hours of culture, media was replaced with 600µl
of 10% alamarBlue in fresh media and incubated for 4 hours. 100µl of alamarBlue media
from each sample was collected in triplicate and read at 600 nm and 570 nm using a plate
reader.
Two experiments were performed with all 12 groups, with three replicates per
experiment (n = 6). One additional replicate for each group was prepared without cells to
serve as a material control. After incubation, each replicate was sampled three times to
be read at 570nm and 600nm and those samples averaged. The percent reductions of
the three replicates were averaged to calculate the percent reduction for that condition.
The material control percent reductions were subtracted from all the replicates.
NGF Sequestration
HepMAHA, HepSHHA, and MeHA fibers were hydrated for at least 24 hours in
PBS, with one PBS change during that time. Each fiber type was tested with and without
NGF loading, as well as with and without NGF-supplemented serum free media, leading
to 12 total groups. To load fibers, 100ng/ml NGF was added to the fibers for 2 hours at
37C, then the fibers were rinsed 7 times with PBS, with at least one overnight rinse. Chick
embryo dorsal root Ganglia (DRG; Charles River, Roanoke, IL) were dissected,
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trypsinized and dissociated as previously described [72]. Cells are resuspended in serum
free media (SFM): DMEM:F12, 2 mM L-Glutamine, 0.6% B27, 50U/ml Pen-strep, and
seeded 10kcells/well. 12.6ng/ml NGF was added to the supplemented SFM groups
(SFM+NGF). After 3 days cells were fixed with 4% paraformaldehyde and stained with
anti-neurofilament NF200 primary antibody, fluorescent 488 secondary antibody (Abcam,
Cambridge, UK) and DAPI to quantify neurite length. Each well was scanned for eligible
neurites. Neurites were counted if (1) they were at least the diameter of the neuron cell
body, (2) they were not touching any other neurites, and (3) they were not in the same
microscope field of view as the edge of the fibers. If a neuron had multiple neurite
extensions, only the longest one was measured. Measurements were done using Image
J (NIH, v1.51K, Java 1.6.0_24, 64-bit) drawing a freehand trace along the neurite.
Statistical Analysis
R Project (R version 3.5.1, 7-2-1018) was used for statistical analysis. Unless
otherwise specified, a one-way ANOVA was performed, with Bonferroni adjusted multiple
comparisons post hoc, when appropriate.
Results
Electrospun Fibers
Example SEM images of MeHA, HepMAHA, and HepSHHA can be seen in Figure
2-1. All fiber types exhibited smooth, even, aligned fibers. All fiber types had similar
alignment. Diameters are presented in Figure 2-1 as mean ± standard deviation; average
MeHA fiber diameter was significantly different from HepMAHA fibers (p<0.05), but all
other fiber combinations were not significantly different. NMR spectra of HepMA and
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HepSH can be seen in Appendix A: Supplementary Figure (1A). Peaks at around 6.0
ppm and 5.5 ppm on HepMA show the methacrylation reaction was successful. Peaks
at 1.2 ppm, 2.9 ppm, and 3.1 ppm indicate successful thiolation as seen in HepSH in
Appendix A: Supplementary Figure 1B [123].

Figure 2-1 Scanning electron micrographs of electrospun fibers.

A: MeHA, B: HepMAHA, C: HepSHHA . The scale bar is 10µm. Micrographs show smooth aligned
nanofibers of similar structure across fiber types. D: Table showing nanofiber concentration.
Nanofiber alignment and fiber diameter is displayed for the three fiber types. Alignment is
percentage of fibers within a 30-degree band, where the band with the greatest percentage of
fibers was found. Fiber diameters are averages ± standard deviation. N=5 SEM images.
(Abbreviations: nanometer, nm)

L929 Fibroblasts
Average percent reduction and standard deviation is reported in Figure 2-2. At 24
hours, loaded HepMAHA had the highest average percent reduction in both regular
growth media and bFGF-supplemented media. Loaded HepMAHA in growth media had
significantly higher percent reduction compared to the other growth media groups
(p<0.05). In FGF-supplemented media, loaded HepMAHA had the highest average
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percent reduction as well, but was only significantly different compared to loaded
HepSHHA (p<0.05).

Figure 2-2 Proliferation of L929 fibroblasts in the presence of Heparin modified nanofibers,
presented as percent reduction of alamarBlue; as cells proliferate, alamarBlue reagent is reduced and can be
reported to approximate proliferation. Loaded fibers were exposed to 100 ng/ml bFGF then rinsed seven times
with PBS prior to cell culture. Standard deviation is indicated by black error bars. A: In growth media, loaded
HepMAHA was significantly different than all other conditions (*, p<0.05). B: In FGF-supplemented media,
loaded HepMAHA was significantly different then loaded Hep SHHA ($, p<0.05).

Dissociated DRG Neurons
At least 3 experiments were performed with the 12 groups described in the
methods, with 1 to 4 replicates per experiment (n = 5 wells minimum). All neurite lengths
from all experiments were averaged for each group, with SFM and SFM+NGF compared
separately (Figure 2-3). The number of eligible neurites, number of wells imaged, and
average number of neurites per well, per group can be seen in Table 2-1. Example
neurites from each group are shown in Figure 2-4.
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Figure 2-3 Average Neurite lengths in the presence of heparin modified nanofibers,
cultured with A: SFM, and B: SFM+NGF. Loaded fibers were exposed to 100 ng/ml NGF then rinsed
seven times with PBS prior to cell culture. Standard deviation is indicated by error bars. * indicates
condition is significantly different than all other conditions (p<0.01). # indicates condition is significantly
different than loaded MeHA (p<0.01). $ indicates condition is significantly different than loaded HepSHHA
(p<0.01). + indicates condition is significantly different than loaded HepMAHA condition (p<0.01).

Loaded and unloaded HepMAHA and HepSHHA incubated with SFM+NGF have
significantly increased neurite lengths compared to loaded and unloaded MeHA (p<0.01).
In SFM, Loaded HepMAHA had significantly longer neurite lengths compared to all other
fiber types (p<0.01).
Table 2-1 Eligible Neuron Metadata Analysis – NGF sequestration
MeHA
SFM
No. of Neurites
Wells Imaged
Average
Neurites/Well
SFM+NGF
No. of Neurites
Wells Imaged
Average
Neurites/Well

HepMAHA

HepSHHA

MeHA

Loaded
HepMAHA
HepSHHA

27
11

62
7

57
10

65
8

91
11

80
10

2.5

8.9

5.7

8.1

8.3

8.0

31
6

55
6

9
5

24
5

67
6

38
6

5.2

9.2

1.8

4.8

11.2

6.3
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Figure 2-4 Example neurite extension on fibers visualized by anti-neurofilament and FITC

All images follow the 100µm scale bar in the top right corner. A through F are neurites grown in SFM. G
through L are neurites grown in SFM+NGF. Neurites are grown on MeHA (A, G), HepMAHA (B, H),
HepSHHA (C, I), Loaded MeHA (D, J), Loaded HepMAHA (E, K), Loaded HepSHHA (F, L).

Discussion
Heparin is known for its traditional role as an anti-coagulant, however its ability to
sequester bioactive molecules has shown promise for tissue engineering applications [97,
112, 120, 121, 129-131, 133, 139]. Brown et al showed two ways to modify heparin such
that it could be conjugated to a biomaterial to be implanted or injected to an injury site:
methacrylation (HepMA) and thiolation (HepSH) [123].

The group evaluated each

material’s anti-coagulation ability to determine heparin’s functionality after modification,
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for which HepSH was more successful than HepMA. However, capability to bind GFs
may be different than the capability to bind antithrombin III for anti-coagulation. As such,
we performed our experiments with both HepMA and HepSH to determine the effect of
heparin modification on GF binding and GF bioactivity. Both materials were conjugated
to hyaluronic acid, a biomaterial naturally found in the central nervous system that has
been used previously for both peripheral and central nerve repair applications [65, 102,
140]. Herein, we evaluated GF binding/sequestration ability of heparin for bFGF and NGF
using fibroblasts and neurons, respectively.
We hypothesized that the bFGF loaded HepMAHA and HepSHHA fibers would
have the ability to sequester bFGF, allowing it to be available to fibroblasts for increased
proliferation compared to both bFGF loaded MeHA fibers and non-loaded fibers. We also
expected that when bFGF is available in the media, all fibers will show similar proliferation
values. We saw that loaded HepMAHA had significantly higher values at 24 hours in the
growth media condition but did not see significant differences with HepSHHA. One
possibility, that would need further investigation, is that perhaps the HepSHHA fibers were
too effective at sequestering bFGF. She et al [141] performed an optimization experiment
on the effect of free floating bFGF concentration on L929 proliferation after three days.
10ng/ml did the best of all groups, with a 50% increase in cell number compared to no
bFGF, but then as the concentration increased, the cell numbers declined [141]. For our
experiment, HepSHHA and HepMAHA fibers were loaded with 100ng/ml bFGF. If a
significant amount of bFGF were sequestered by HepSHHA fibers, then when the cells
were cultured in 1ml of media for the duration of the experiment, the cells could be
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exposed to a substantially higher concentrations of bFGF, leading to lower cellular
proliferation. Lower concentrations of bFGF will be tested in future experiments.
We also hypothesized that FGF supplementation would increase fibroblast
proliferation. We found bFGF-supplemented groups had similar or lower levels of
proliferation as compared to the growth media groups. Including bFGF in the media did
not positively affect cell proliferation. This may be due to the presence of serum in the
media, which can contain cell favorable components [142] or oversaturation of bFGF as
described above. A study by Zheng, et al performed a proteomic analysis of three different
lots of fetal bovine serum from two different suppliers and identified seven different GFs
in the three sera [142]. If the serum in our experiments contained bFGF or other
fibroblasts promoting GFs, this could have a confounding effect on proliferation. A small
trial of serum free media was performed (data not shown), in which HepSHHA performed
similarly to HepMAHA and the FGF-supplemented serum free media appeared to have
higher proliferation rates than the serum free groups, though this was not significant. A
more thorough experiment would be needed to confirm this. L929 proliferation assays
have been performed with [143-146] and without serum previously [141, 147-149] These
serum data are valuable because in vivo, there is no doubt that other growth factors and
proteins would be present along with the sequestered GF.
Another factor that may reduce our ability to evaluate a difference in L929
proliferation is the timing of the experiment. Many L929 experiments are performed for
more than 7 days, with multiple proliferation measurements throughout that time [141,
143-147, 150, 151]. Of those referenced studies, two were testing the effects of
sequestered [146] or microcapsule delivered bFGF [141], only one of which collected a
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24 hour time point and found no significant differences at 24hrs [146]. We attempted
longer time points in our L929 proliferation experiments, however we found that with time,
fibroblasts migrated off the nanofibers and proliferated on the tissue culture plastic, which
masked the effect of the fibers on L929 proliferation. Our 48-hour time point showed
Loaded HepMAHA had the highest averages in both growth and bFGF-supplemented
media, but the difference was not statistically significant (data not shown). By 72 hours,
all of the groups looked the same. Other papers addressed this issue by either making
their materials the exact size of the well [151], fixing the material in a glass cylinder [144],
or by coating the 24 well plate with parafilm to discourage growth off of the tested
materials [145]; none of the listed papers transfer the fibers to new plates before collecting
proliferation data as we did. It is possible that our method to combat fibroblast migration
resulted in the large error bars seen in Figure 2-2. Future experiments could be performed
over longer periods and obtain smaller error bars if we address the L929 migration issue,
however the fact that HepMAHA fibers have a significantly higher proliferation at 24 hours
is promising.
We have previously shown that Chick DRG neurons respond to NGF [65] and
neurite length increased with increasing NGF concentration. If the fibers are capable of
sequestering NGF, then neurites cultured with SFM on NGF-loaded fibers should react
as though NGF is present throughout the 3-day experiment. This is shown by increased
neurite lengths of dissociated DRGs on loaded HepMAHA and HepSHHA fibers
compared to loaded MeHA fibers and all fibers that were not loaded (Figure 2-3). We
expected that all the neurons would have increased neurite lengths when cultured with
SFM+NGF, however we found that HepMAHA and HepSHHA fibers, loaded and
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unloaded, showed longer neurites than MeHA fibers with SFM+NGF. NGF was added at
the beginning of the three-day experiment, and not refreshed. The soluble NGF may have
degraded after the first day due to the short half-life of growth factors [152], unless they
were bound by heparin in the HepMAHA and HepSHHA groups. In the SFM groups, the
loaded groups were all higher than the unloaded groups, though HepMAHA had the
longest neurites of all groups (α<0.05). These data show that heparin can be modified
and crosslinked to MeHA, electrospun, and still bind functional neurotrophic factors.
The number of neurites measured in each group is reported in Table 1. Dissection
of DRGs from chick embryos can be inconsistent due to biological variability, the number
of DRGs harvested, DRG location and the effectiveness of dissociation. Due to these
reasons, there was variation in the number of wells imaged and total number of neurites
measured between groups, which could account for the large standard deviations seen
in Figure 2.3. There was a low number of attached and eligible neurons per well in the
unloaded MeHA group cultured in SFM; many neurons were lacking neurites or were
simply absent.

In total, six SFM experiments were performed to obtain 27 eligible

neurites within 11 wells for unloaded MeHA. For comparison, only three experiments
SFM+NGF yielded 31 neurons in 6 wells. SFM+NGF unloaded HepSHHA also has a low
average of eligible neurons per well, however this was not always due to a lack of
attached neurites. Both loaded HepMAHA and loaded HepSHHA visually had many
neurons, however many were disqualified from imaging and analysis due to contact with
other neurons. Future experiments would benefit by counting the total number of neurites
or neurite clusters as opposed to only the ones eligible for measurement. It is interesting
that the number of cells per well was high for HepMAHA fibers regardless of loading and
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regardless of media. Combining these data with the neurite lengths indicate that the
hepMA on its own may help encourage cell attachment even if it doesn’t help with growth.
Many studies have considered the effect of heparin to help GFs be more effective [83,
86, 112, 119, 121, 129-131, 135, 139, 153-156], and by aiding GFs increase attachment
[153, 157-159] but not many investigate heparin by itself [160, 161]. Eisenbach et al[161]
found that soluble heparin specifically inhibited certain types of cell-produced
neuroregulin that led to enhanced myelination of Schwann cells in a mouse and rat DRG
cultures, but no change in proliferation of Schwann cells or neurons. Considering this
with the attachment data from Table 1, the presence of heparin may encourage neuronal
attachment, due to uptake of attachment proteins or GFs produced by cells, or by aiding
Schwann cells to support the neurons.
A heparin biomaterial that can sequester active GFs would be ideal for wound
environments, where the natural response of clearing the area would otherwise increase
degradation and diffusion of free floating GFs away from the injury site [152, 162]. Most
GFs have very short (minutes to seconds) half-lives in vivo; bFGF was measured to have
a 1.5 min half-life after intravenous injection [152, 163] while NGF was measured as a 2.4
min half-life [152, 164]. Heparin has been shown to protect bFGF from degradation after
IV injection [163], in vivo [119, 131, 153] and in vitro [97, 112, 121, 130, 141]. Heparin
has previously been used to enhance the availability of NGF [83, 120, 154-156, 165] and
a combination of FGF and NGF [155, 165] Herein, we have shown that HepMAHA fibers
can sequester bFGF and NGF and can create a conducive environment for neuronal
growth. This nanofibrous material can be used with GF releasing microspheres to provide
active GF for a longer duration, along with a nanofibrous matrix for topographical cues
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known to enhance neuron growth. NGF was chosen for this study due to its effect on
DRG neurons, however, for future spinal cord studies, we will incorporate brain-derived
neurotrophic factor (BDNF). Future steps for spinal cord injury repair are to include bFGF
and BDNF in microspheres within the fibers, such that these factors can be released in a
controlled manner with the intent of preventing secondary tissue loss and increasing
neuronal growth for SCI recovery.

Acknowledgements
This research was supported in part by a US Department of Defense Grant (W81XWH16-1-0102).

45

CHAPTER 3: MACROPHAGE MEDIATED GROWTH FACTOR RELEASE FROM
GELATIN MICROSPHERES
Introduction
SCI affects approximately 291,000 people in the United States, with an estimated
17,730 new cases per year [8]. Though there is no current gold standard of care, tissue
engineers have found several factors that help with SCI regeneration, mainly:
chemoattraction, growth permissive substrates, and reactivation of intrinsic growth
capacity [48]. Strategies typically in involve an injectable hydrogel or a nerve guide
conduit with modifications that provide mechanical, topographical, chemical, and/or
electrical cues to guide neuronal growth [53, 106]. Aligned nanostructures, such as
nanofibers or intraluminal channels, can provide the topographical track for neurons to
follow, while GFs can be delivered to encourage neuronal growth or aid cellular support
systems [48, 53, 87, 122].
Delivery of multiple GFs at the same time has received mixed results, highlighting
a need for spatiotemporal delivery similar to that seen in the native SCI timeline to avoid
antagonistic effects [31]. While immediate release of GFs has been done extensively [3,
65, 87, 95, 114, 155, 166-169], the delayed release is still being explored. Current
methods of delayed release include: triggered release based on a stimulus [170, 171],
single or double encapsulation [107, 111], lentiviral gene expression [99, 172], and cell
mediated degradation [124]. Of these, the cell, or more specifically M1 macrophage,
mediated delayed release is ideal for the growth factor release profile following SCI.
Annamalai et al. created gelatin microspheres (GMS) that degraded preferentially in the
presence of M1 macrophages, a tactic that their group used to deliver BMP2 during the
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inflammatory phase of bone regeneration and aid the transition to a regenerative phase
[124]. In our study, we employ similar methods to use the immune response in SCI to
dictate when the GF is released. Peripheral blood monocytes invade the SCI environment
immediately after the initial trauma, but macrophage invasion peaks at around 3-4 days
in mice [46] and 5-7 days in humans [31]. The cytokines seen in this time frame are
indicative of M1 macrophages [46], and so would increasingly degrade GMS over the
several days after the injury or surgery, releasing GF stored within. Several neurotrophic
factors are upregulated 6 hours after injury, with peak expression occurring up to 4 days
after that [46]. In future studies, a combination of immediate release GF delivery, and
macrophage mediated GF release would allow for the spatiotemporal GF release needed
for SCI repair while avoiding antagonistic effects [9, 173]. For this paper, we investigate
the feasibility of obtaining a delayed, macrophage mediated GF release from GMS
electrospun into nanofibers.
Previously our lab has electrospun poly(lactic-co-glycolic) acid microspheres
together with methacrylated hyaluronic acid (MeHA) to create aligned nanofibers with
topographical and immediate biochemical cues for neuronal growth [3, 65]. Here, GMS
were produced, optimized, and then combined with MeHA in solution and electrospun to
create GMS fibers (GMSF). To determine that GMS were degraded and that functional
GFs were released only in the presence of M1 macrophages, dissociated chick dorsal
root ganglia (DRG) were grown for three days on MeHA, GMSF without GF, and GMSF
with NGF in various media conditions. Serum Free Media (SFM) and SFM containing
25% monocyte conditioned media (M0CM) were used as control media conditions. SFM
with 25% M1 macrophage conditioned media (M1CM) was used as the experimental
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group. We hypothesized that neurons grown on GMSF with NGF would exhibit longer
neurites only in M1CM, showing that GMS electrospun into MeHA nanofibers would
release functional NGF, mediated by M1 macrophages.
Methods and Materials
Unless specified otherwise, materials were obtained from Thermofisher Scientific. Fiber
diameter and alignment measurements were the same stated in Chapter 2, (page 31)
Gelatin Microsphere Protocol
GMS were made from a single emulsion of gelatin in heated olive oil. Briefly,10
mls of 6% wt gelatin from porcine skin (175g Bloom, Type A, Sigma) was added dropwise
to 250 ml of olive oil (Colavita, Campobasso, Italy), while stirring at 700RPM, 1100RPM,
or 1200RPM, at 45oC for 10 min. The solution temperature was then reduced to 4oC over
30 min, continuing to stir. GMS were precipitated with 100 ml of chilled acetone, stirring
for an hour. A further 100 ml of acetone was added and then the solution stirred for 5
minutes. GMS were filtered, washed with acetone, and air dried. A 1%wt genipin solution
in PBS was used to crosslink the microspheres for at least 16 hours, or until visually
crosslinked as per the color change from orange to a dark purplish blue. Crosslinked GMS
were centrifuged, rinsed with deionized water three times, then frozen and lyophilized for
storage. Before use, the GMS were hydrated in either a growth factor solution or PBS
overnight at 4˚C.
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Crosslinking GMS evaluation
Annamalai et al [124] found that 90% crosslinked GMS were necessary for M1
macrophage degradation specificity. To ensure this was achieved, 0.01g of noncrosslinked GMS were placed in a 96 well plate, 3 wells per group per time point (n=3),
had 250ul of 1% genipen or PBS added to each well at specific times, then read with a
plate reader at 590nm to measure the optical density of the all supernatants. Four total
groups were tested this way: 700RPM + Genipen, 700RPM +PBS (i.e. non-crosslinked,
control), 1200RPM +Genipen, and 1200RPM +PBS. The wells for the 8hr timepoint were
given 1% Genipen or PBS solutions in the morning, 8 hours before the plate was read in
the evening. The next set of samples were given solutions 5 hours before, then 3, 1, and
0.5 hours before the plate was read. The next day, the same plate was read again in the
morning to record the samples at 24 hours to 16.5 hours, and then read again in the
evening to give 30 hours to 22 hours.
GMS diameter analysis
GMS were imaged with brightfield microscopy. 700RPM GMS diameters were
measured by hand using the Nikon AR Elements camera software. 1100RPM and
1200RPM GMS diameters were measured with the MATLAB function imfindcircles(). The
function parameters were determined via trial and error on a few sample images, such
that the lighting and contrast of the image set were considered, before batch processing
10 images from 1100RPM and 1200RPM GMS. The function also outputs the counted
images and a spreadsheet. In post-processing, counted images were checked for any
blatant errors, and the measurements from those errors were removed from the data.
Matlab code is provided in Appendix B
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GMS loading and loading efficiency
Crosslinked and dried GMS were loaded with NGF (GMS+NGF) by hydrating in 10
µg/ml NGF solution overnight at 4˚C. For each mg of microspheres, 10µl of NGF solution
was used. Extra GF solution was prepared for loading efficiency calculations. As a
control, empty GMS (GMS+Ø) were hydrated in PBS only. After hydration, 3 mls of PBS
were added to help with initial supernatant collection; GMS were centrifuged for 3 min at
2000RPM and the supernatant was collected and frozen until use in loading efficiency
ELISA. GMS were then rinsed with 1mg/ml BSA in PBS two times, removing as much
liquid as possible after the third rinse. GMS were used immediately after GF loading for
either degradation experiments or for electrospinning.
Loading NGF solution and after hydration GMSF+NGF (N=5) supernatants were
compared in triplicate with an indirect enzyme-linked immunosorbent assay (ELISA) to
calculate loading efficiency: ([loading solution] – [GMS supernatant]) / [loading solution]
= Loading efficiency%. Of the 3mls collected for loading efficiency calculations, 100ul
was diluted into 5mls PBS. GMS+Ø control was also compared, to counteract any effects
of the gelatin on the reading.
NGF release profile
GMS+NGF in collagenase (n=3) and in PBS (n=2) were incubated at 37˚C for 10
days to evaluate GF release with and without 5 U/ml collagenase (Worthington
Biochemical Corporation, Lakewood, NJ. CSLPA). At 1, 3, 8 hours and then 1, 2, 3, 4,
and 7 days, 200µl of supernatant was collected and frozen until ELISA was performed.
Clear, flat bottom, hydrophilic plates were incubated with 1:50 diluted sample supernatant
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for 2hrs at room temperature, rinsed three times with ELISA wash buffer and then
incubated overnight at 4˚C with 10% normal goat serum. Plates were then incubated with
Anti-NGF (1:200 or 1:500 PA1-9516, polyclonal) for 2 hrs at room temperature, rinsed
four times with wash buffer, and then incubated with an HRP conjugated secondary
antibody (A16054) for 2 additional hrs.

TMB ELISA substrate (High Sensitivity,

ab171523, Abcam, Cambridge, UK) was added to each well for 10 minutes, while the
plate was kept in the dark and shaken.

450nm Stop solution (ab171529, Abcam,

Cambridge, UK) was added and plates were read within 30 min. Wash buffer consisted
of PBS, 1% BSA, and 0.1% Tween. GMS+Ø with (n=3) and without collagenase (n=2)
were evaluated as controls.
Electrospinning MeHA nanofibers with and without GMS
HA was methacrylated as previously described: 20 molar excess of methacrylic
anhydride added dropwise to 1% w/v HA in deionized water over ice and maintained at
pH 8.0 [28, 31]. The resulting MeHA solution was then dialyzed, lyophilized and stored at
-20C until use. The base electrospinning solution was made from 2% w/v MeHA, 3% w/v
polyethylene oxide, and 0.05% Irgacure 2595 photocrosslinker in DI H2O [28]. For
GMS+Ø and GMS+NGF, 30mg microspheres were added per 1 ml electrospinning
solution. MeHA was electrospun at 22kV for 30min, MeHA with GMS+Ø (GMSF) and
MeHA with GMS+NGF (GMSF+NGF) were electrospun at 24kV for 30 min, with extra
care that the collection mandrel temperature not exceed 37˚C. All fibers were crosslinked
using a 365 nm wavelength UV light. GMSF+NGF were parafilmed and stored in 20˚C
until use. Scanning electron microscopy (SEM) was performed on gold sputtered fibers
using a tungsten JSM 6510LV.
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Preparation of CD14+ Monocytes from Peripheral Blood
Peripheral blood was drawn from healthy adult donors under an IRB approved
protocol (#1010008973). Peripheral blood mononuclear cells (PBMC) were isolated via
density gradient centrifugation using Ficoll- Paque® following standard protocol. CD14+
monocytes were then isolated from the PBMC using EasySep™ Human Monocyte
Isolation Kit (Stemcell Technology) following published protocol [174].
Monocyte Cell Culture and Induction of M0 and M1
CD14+ cells were seeded 500kcells/well into a 12-well plate in Roswell Park
Memorial Institute (RPMI) Media containing 10% fetal bovine serum and incubated at
37˚C for 2-4 hours for the cells to adhere. 100U/ml Granulocyte macrophage colonystimulating factor (GM-CSF) was added into all wells and incubated for 24 hours. To
induce an M1 state, the media was replaced with complete RPMI containing 200U/ml
GMCSF, 100ng/ml LPS, and 100ng/ml interferon-gamma (IFN-g). In control (M0) wells,
RPMI containing only low-dose 100U/ml GMCSF was added. The media was replaced
with fresh RPMI containing cytokines after 48 h and the cultures were further incubated
for 48 h. The culture supernatants (M0CM and M1CM) were collected, passed through a
0.45 µm syringe filter and stored at -20C until use. Cytokine analysis of interleukin 6 and
10 (IL-6, IL-10) in conditioned media was performed via ELISA (R&D systems,
Minneapolis, MN), and M1 transformation was confirmed via elevated IL-6 secretion in
M1CM as compared to M0CM.
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NGF release from nanofibers
Chick embryo dorsal root Ganglia (DRG; Charles River, Roanoke, IL) were
dissected and dissociated as previously described [72]. Dissociated cells were
resuspended in serum free media (SFM): DMEM:F12, 2 mM L-Glutamine, 0.6% B27,
50U/ml

Pen-strep, and seeded 10kcells/well.

Neurons on MeHA, GMSF, and

GMSF+NGF fibers were cultured in SFM, SFM containing 25% M0CM, and SFM with
25% M1CM, for a total 12 groups. A minimum of 7 wells (n=7) per group were evaluated
over four experiments, each experiment lasting three days.
Cells were fixed with 4% paraformaldehyde and labeled with anti-neurofilament
NF200 primary antibody (Sigma Aldrich, St. Louis, MO), visualized with fluorescent 488
secondary antibody and counterstained with DAPI to show cell nuclei. Each well was
scanned for eligible neurons, which were then imaged. Neurons were considered if their
neurite length was as least as long as the diameter of the cell body. If a neuron had
multiple neurite extensions, the longest one was measured. Neurons that were touching
other neurons were not considered.

Image J (NIH, v1.51K, Java 1.6.0_24, 64-bit),

freehand tool, was used to measure the neurite lengths.
Statistical Analysis
Statistical analyses were done with R-Project (version 3.5.1, updated 7.2.2018,
downloaded from UC Berkeley).
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Results
GMS characterization
All three mixing speeds produced GMS that could be collected, crosslinked and have their
diameters measured. As GMS become crosslinked, they turn from a pale orange to
purplish gray to dark purplish blue after the overnight incubation. Figure 3-1 shows the
optical density of crosslinking GMS collected over the course of 30 hours. Optical density
appeared to plateau after 8 hours for 1200RPM GMS, and after 20 hours for 700RPM
GMS

After crosslinking, GMS diameters were measured (Figure 3-2). We decided to

move forward with 1200RPM microspheres, which exhibited the least amount of variation
of diameters and were the fastest to crosslink. Any reference to GMS from here forward
will be specifying 1200RPM GMS.
4.5

GMS Crosslinking - Absorbencies over time
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Figure 3-1 GMS crosslinking confirmation
0.01g of 700RPM or 1200RPM GMS were added to each well of a 96 well plate, then 1% Genipen was
added to three wells of 700RPM (blue) and 1200RPM (gray) at each timepoint. PBS was added to three
wells of 700RPM (orange) and 1200RPM (yellow) at each timepoint as a control.
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Figure 3-2 GMS visualized with brightfield microscopy
A) 700RPM, B) 1100RPM, and C)1200RPM. All images are taken at the same magnification, A, B, and C
are to scale, scale bar is 500 um. D) Microsphere diameters.

GMS were confirmed to release NGF with exposure to collagenase (Figure 3-3)
over the course of 7 days, with a loading efficiency of 99.8%. Coefficient of variance
(standard deviation of a triplicate/mean of a triplicate) were under 20% for all triplicates.
GMS+NGF in collagenase releases NGF immediately after adding collagenase and
steadily increases over the first 24hours. GMS+NGF in PBS is initially negative at 0hrs,
reaches 10.59 ng/ml ± 1.8ng/ml at 1 hr, and then declines to negative values by 24hours.
GMS+Ø in both collagenase and PBS are initially negative and slowly become less
negative but remain close to zero.

55

NGF Release
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Figure 3-3 NGF Release Profile (first 24hours)
100µg of GMS were hydrated in 10µg/ml NGF (GMS+NGF) or PBS (GMS+Ø). GMS+NGF was incubated
at 37˚C in 5U/ml collagenase (blue) or PBS (green). GMS+Ø was also incubated in collagenase (orange)
and PBS (yellow). Error bars represent the standard deviation. Coefficient of variance (Cv) for each well in
the 96 well plate was less than 20%.

Electrospun nanofibers
GMS were successfully combined with MeHA while electrospinning (Figure 3-4). Five
SEM images were analyzed using DiameterJ plugin to determine an average fiber
diameter of 365 ±10 nm and 44% ± 8% alignment. GMS in images analyzed for diameters
and alignment were found to skew the results, particularly with GMS that filled most of the
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image. As such diameters and alignment were taken from images with minimal GMS
presence.

Figure 3-4 SEM of GMSF
GMSF are successfully incorporated into the MeHA nanofibers. A) 20x magnification of GMSF, arrows
indicate a few GMS, though there are more throughout the nanofibers. Scale bar is 1mm. B) 2000x
magnification of a single GMS within the MeHA nanofibers. Scale bar is 10um

NGF release from nanofibers
The average neurite lengths per experimental group can be seen in Figure 3-5.
MeHA in SFM, M0CM, and M1CM all had similar neurite lengths, with a slightly higher
average in M1CM, though not significant. GMSF had a similar trend, though GMSF in
M1CM was statistically different from MeHA in SFM and M0CM, as well as GMSF in
M0CM (p<0.05). GMSF+NGF in all media conditions was significantly different from
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NGF Release from Nanofibers
Average Neurite Lengths
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Figure 3-5 NGF release from nanofibers - Average neurite lengths
Dissociated chick DRG neurons were cultured on three fibers types, with three media conditions; MeHA (blue),
GMSF (orange), and GMSF+NGF (green) are shown grouped by media condition, where M0CM is SFM+
25% M0CM and M1CM is SFM+ 25% M1CM. Error bars indicate standard error of the mean. * is used to
indicate data is significantly different compared to MeHA in SFM (p< 0.05); # indicates a difference (p< 0.05)
compared to MeHA in M0CM; $ indicates a difference (p<0.05) compared to GMSF in M0CM

MeHA in SFM and M0CM (p<0.05). GMSF+NGF in M1CM was also significantly different
from GMSF in M0CM (p<0.05). Error bars represent standard error of the mean.
There was a minimum of 7 wells per group, however there were up to 12 wells
evaluated for some groups. Table 3-1 shows the metadata regarding neurite
measurement. The number of eligible neurons per well were highest in all GMSF+NGF
groups, with GMSF+NGF in M1CM exhibiting the highest number at 11.1 neurons/well.
Example fluorescent images of neurites are provided in Figure 3-6.
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Table 3-1 NGF Release from nanofibers metadata analysis
Media

SFM

M0CM

M1CM

Fiber Type

MeHA

GMSF

GMSF
+NGF

MeHA

GMSF

GMSF
+NGF

MeHA

GMSF

GMSF
+NGF

Total wells
per group

11

11

12

11

11

12

8

8

7

No. of
neurons

37

46

82

58

36

96

13

22

78

Average
Neurons/well

3.4

4.2

6.8

5.3

3.3

8.0

1.6

2.8

11.1

MeHA

GMSF

GMSF+NGF

SFM

M0CM

M1CM

Figure 3-6 Example neurites per group in NGF release from nanofibers.
Neurofilament is labeled with FITC (green), nuclei are counterstained with DAPI (blue)

Discussion
In this paper, we investigated the ability of GMS loaded with NGF to be electrospun
within MeHA fibers and release bioactive GF. We further investigated the release of NGF
from GMS in the presence of collagenase and M1 macrophage conditioned media. The
overall goal was to establish GMS as a GF delivery vehicle that would be mediated by
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macrophages and, more generally, an inflammatory response. This is particularly
important within SCI, as the inflammation response during the acute phase of secondary
damage is responsible for cell death and axonal dieback [7, 9, 29, 31], with an influx of
macrophages occurring after 1 day, and peaking after 3-4 days in mice and 5-7 days in
humans [31, 46]. Ideally, GMSF could be used as an implantable biomaterial to deliver
GFs in response to inflammation within SCI. Further, the delay could be used for GFs that
are present at later stages within the SCI timeline.

For example, brain-derived

neurotrophic factor is seen about 6 hours after injury, peaks at about 3-4 days and steadily
increases for 6 weeks [30, 46], meaning GMS could be a reasonable vehicle for BDNF in
a SCI environment.
GMS were successfully made at three different sizes, then evaluated for
crosslinking time.

Different sizes ranging from 36.57µm ± 12.22µm to 203.41µm

±106.06µm were accomplished by changing the speed at which the olive oil was spinning
while the gelatin solution was added, via the stir plate dial. As the speed was increased,
the diameters and variation of diameters decreased. Regarding crosslinking time, only
1200RPM and 700RPM were compared. Annamalai et al, created GMS for use in bone,
which also has an extensive inflammation response with injury, and were shown to
degrade and release BMP2 preferentially by M1 macrophages [124, 175]. In that study,
GMS were 12.4µm ± 2.9 µm and considered more than 90% crosslinked after 12 hours
[124]. Initial batches of GMS were crosslinked for only 12 hours, however, sometimes the
GMS were only a pale grayish purple. Lau et al [176] performed a series of tests to
determine optimal genipen solution, and found that temperature and genipen solubility
played an important role for crosslinking times. Further, they showed that fully crosslinked
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GMS in their chosen genipen and ethanol solution turned to a dark purplish blue [176].
Due to this, the crosslinking experiment was performed to confirm crosslinking at room
temperature with 1% genipen in PBS.
There was some issue with GMS at the bottom of the well blocking the reading in
the 1200RPM group, so some timepoints are missing data. The 700RPM and 1200RPM
GMS incubated in plain PBS remained in a plateau around 1 – 1.5 OD.

After about 5

hours the 700RPM and 1200RPM GMS were above 2 OD, distinct from their PBS
counterparts. The experiment was carried out for 30 hours in order to ascertain a plateau,
which could be considered 100% crosslinked. 1200RPM reached a plateau around 3.5
OD by 8hrs, whereas 700RPM reached a plateau at about 16.5 hours . With the size
distribution and the crosslinking data, 1200RPM GMS were used for the remainder of the
study, and crosslinking time was increased to 24 hours to ensure the plateau was
reached. The visual cue of a dark blue liquid and purplish-blue GMS also aided for
determining if GMS were fully crosslinked. In future studies, crosslinking percentage could
be confirmed using either a fluorometric plate reader or by measuring zeta potential [124,
177].
We further characterized GMS for loading efficiency and NGF release.

The

loading efficiency was calculated by comparing the concentration of NGF in the leftover
loading solution, frozen after NGF loading started, to the concentration of NGF in the
supernatant collected after loading for 16 hours and before rinsing the GMS as
preparation for electrospinning or the NGF release assay. The loading efficiency was
calculated to be 99.8%. This would translate to about 99.8 ng NGF per mg of GMS, which
is well below the 640ng BMP2 per mg GMS encapsulation capacity reported in Annamalai
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for BMP2 [124]. As such, a 99.8% loading efficiency is reasonable to expect. For the
NGF Release ELISA, we degraded 100mg of GMS with and without NGF over time with
chromatographically purified collagenase. This experiment was based on a similar
analysis performed by Annamalai et al [124]. For each timepoint, 200µl was collected
from an initial 6ml of PBS or 5U/ml collagenase in PBS. As such NGF concentrations
determined via the ELISA were cumulative. In GMS+NGF we found most of the NGF
was released after 8 hours of incubation, with a high of 258.5 ng/ml . At the 24 hr timepoint
we saw a decrease to 236.2 ng/ml hours, and then more of a decrease to 124.0 ng/ml at
48 hrs, after which there was a plateau in NGF concentration. This decrease could be
due to the half-life of NGF; once NGF is released from the affinity bond to GMS it would
be susceptible to hydrolytic degradation. GMS+NGF in PBS showed a slight increase at
1 and 3 hours of incubation, as compared to the GMS+Ø control groups. We expected
that some amount of NGF may be present on the exterior of the GMS or even diffuse out
of the GMS without the need for collagenase degradation. With the ELISA data, we find
this amount to be about 37.1 ng/ml NGF . However, the NGF concentration values for
GMS+NGF in PBS were indistinguishable from GMS+Ø in collagenase and PBS after 8
hours, measuring 25.3, 22.9, and 32.7 ng/ml NGF, respectively. This experiment was
performed to determine if the GMS could be trusted to deliver GFs only in the presence
of collagenase, and the data shows a distinct difference between GMS+NGF in
collagenase vs PBS.
One important note before continuing, M1 macrophages are generally accepted to
secrete several types of collagenase [178, 179]. However, when characterized, M1
macrophages are often tested for specific matrix metalloproteinases (MMPs), such as
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MMP1,2,3, 7 and 9 [178, 179]. Though we have not currently characterized which
collagenase is present in our M1CM, we plan to perform such characterization in the
future.
GMSF neurite data was not as expected but did provide some insightful results.
We expected for SFM to produce the shortest neurites, in all fiber groups. Though we
also considered that both GMS and the possibility of excess NGF not fully rinsed from
GMS+NGF could affect this media condition. We also expected that M0CM and M1CM
would have some effect on all fiber types. We hypothesized that GMSF+NGF in M1CM
would produce the longest neurites of all groups, due to the degradation of GMS+NGF.
However, this was not the case. GMSF+NGF in all media conditions produced
significantly longer neurites than MeHA in SFM and M0CM (α<0.05). GMSF in SFM and
M0CM was also higher than MeHA in SFM and M0CM, but not significantly so. This leads
us to believe there is some NGF affecting the neurons in all GMSF+NGF fiber groups
regardless of media.
In chapter 2, neurons without NGF averaged about 50 to 100 µm, while neurons
on MeHA in NGF-containing media averaged about 100µm, and neurons with
sequestered NGF measured close to 300µm [180]. Another group using 10ng/ml NGF
in neurobasal media, supplemented with B27, penicillin, streptomycin, and L-glutamine,
had neurites lengths at about 120µm after 24hours [181]. Here we use DMEM:F12
instead of neurobasal media, but otherwise similar supplements and had averages below
100µm, albeit it with high variation in GMSF+NGF groups and GMSF in M1CM. This
raises the question of: what is the minimum amount of NGF to elicit a response from
dissociated chick DRG neurons? Lin et al (2016) performed an optimization experiment
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which tested NGF solution concentrations from 0.16 to 5 ng/ml, using dissociated DRGs
cultured on laminin coated surfaces for 3 days [182]. They found that dosages from 0.63
to 5 ng/ml produced longer neurites than 0, 0.16, and 0.31 ng/ml NGF, though none of
the results were statistically significant [182]. Other studies have used as low as 0.05 0.5 ng/ml to affect neurite extension [183, 184]. Considering the NGF Release profile,
with the small release of NGF, it is possible that this was enough to effect the neurites,
regardless of media condition.
However, this does not explain why GMSF on average produced longer neurites
than GMSF+NGF in M1CM and MeHA in all serum conditions. Additionally, both fibers
GMSF and GMSF+NGF in M1CM had significantly different results from GMSF in M0CM,
but not significantly different from MeHA in M1CM. This leads us to believe two things, 1)
that degraded gelatin may influence dissociated DRGs similar to the effect that NGF does,
and 2) something in M1CM aids neurite outgrowth.
Considering the individual neurons (Appendix C: Neurite Data Boxplot), the only
groups to include neurites longer than 250µm were the GMSF+NGF. These neurite
lengths are on par with what we saw previously in Chapter 2 for fibers with heparin.
Gelatin is not considered to have heparin binding domains, however perhaps there are
other interactions that could cause sequestration of GFs. This could in turn explain why
GMSF in M1CM produced comparable average neurite length, particularly in conjunction
with the presence of cytokines in the media.
Collagen is well known for including heparin binding domains [131, 185-187];
however, gelatin is a denatured form of collagen and heparin or collagen is often added
to gelatin to increase GF binding [123, 158, 188-190]. However, the effect of gelatin on
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GF sequestration was not insignificant, and a recently published review elaborates on the
affinity based sequestration that gelatin is capable of [112, 188, 191]. Briefly, gelatin can
be positively or negatively charged based on the purification method, and this charge can
hold GFs within the hydrogel mesh that GMS are composed of [191]. Depending on how
tightly this mesh is formed, GFs can be held safely within the GMS or GFs can diffuse out
and be vulnerable to degradation [191]. If crosslinking was not actually 100%, as would
be difficult to completely affirm without a fluorometric plate reading or zeta potential
measurement [124, 177], then it’s possible the hydrogel mesh is loose enough for both
NGF to diffuse out and for other factors to diffuse in. This affinity sequestration could also
explain why NGF concentration reached a plateau in the NGF Release assay, as opposed
to becoming completely degraded. Combined with the affinity binding and general
attachment properties of gelatin, the longer neurite extensions in GMSF in SFM and
M0CM makes sense.
If the GMS is holding GFs via affinity binding, and GMSF in M1CM has comparable
neurite lengths to GMSF+NGF in M1CM, what could be in M1CM that may be
sequestered and aid neurite growth? A recent review article list 12 (human) to 14 (mice)
cytokines, chemokines, and other macrophage secreted molecules that are considered
pro-inflammatory [192]. Of, these IL-6 has often been considered a neurotrophic cytokine
[193-195] though it also degrades quickly if not bound [196]. Further, we used elevated
IL-6 secretion in M1CM as compared to M0CM as our metric for successfully transformed
M1 macrophages; as such we know that IL-6 is present. We see in MeHA in M1CM a
slight increase in average neurite length compared to MeHA in other media conditions,
which could be due to the presence and then degradation of IL-6. We saw a similar effect
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in Chapter 2, where NGF added at the beginning of the 3-day experiment seemed to have
little effect on the neurites, except in cases where NGF was actively sequestered by
HepHA. In this case, with GMSF and GMSF+NGF, we could be seeing some amount of
sequestration by the gelatin, for both cytokines in M1CM as well as the loaded NGF.
Though we have an unexpected possibility of affinity binding with GMS, we do
achieve the basic goal of having increased neurite lengths, and GF release, in the
presence of collagenase and M1CM. For future experiments, we plan to combine these
macrophage mediated GF release GMS with hydrolytically degraded poly-lactic-goglycolic microspheres, used previously in our lab [3, 65]. Further, we plan to incorporate
both microspheres into heparin-hyaluronic acid nanofibers which have been shown to
sequester functional GFs in vitro (Chapter 2) [180].

Together, this will provide a

spatiotemporal GF delivery system, that we plan to test in an organotypic spinal cord
injury model.
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CHAPTER 4: COMBINED SPATIOTEMPORAL SYSTEM AND ORGANOTYPIC
SPINAL CORD MODEL DEVELOPMENT
Introduction
Spatiotemporal growth factor release is a promising regeneration strategy for
spinal cord injury (SCI) [7, 31, 48]. SCI is a multiphase event involving many different
cells, cytokines, and growth factors throughout the phases [7]. After the initial damage in
the primary phase, the secondary phase describes the reaction to injury, further split into
acute, subacute, and chronic phases [7, 46]. Immediately after injury during the acute
phase, microglia, astrocytes, and peripheral monocytes migrate to the site and secrete
inflammatory cytokines and enzymes contributing to tissue necrosis and axonal dieback
[7, 29, 30, 46, 47]. The acute phase also sees a release of GFs that protect
oligodendrocytes (OLs) and encourage neuronal growth. Up to two weeks after injury, the
subacute phase is characterized by phagocytic activity, macrophage invasion, increased
number of reactive astrocytes, and glial scar formation [7]. Several GFs released in the
acute phase continue to be expressed well into the subacute phase. As an example:
bFGF is seen at 1hour after injury, but peaks at 2-3 days and lingers until 14-21 days [46].
BDNF release, which is activated by the immediately released acidic fibroblast growth
factor, is detected after 6 hours from SCI, builds up for 6 weeks, then diminishes after 12
weeks [46, 47]. By the chronic phase, starting around 6 months after injury, the blood
brain barrier has been re-established by a completed glial scar, and the dystrophic growth
state continues indefinitely [7, 30, 34, 46].
Considering this timeline, it seems beneficial to deliver a biomolecule immediately
to combat tissue necrosis, such as bFGF, and then deliver a biomolecule to aid with
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remyelination and neuronal extension past the glial scar, such as BDNF. Our lab has
previously developed the components for a spatiotemporal growth factor delivery system
which comprises of heparin-hyaluronic acid (hepHA) nanofibers to sequester released
growth factors (Chapter 2, [180]), hydrolytic GF release with PLGA microspheres [3, 65],
and M1 macrophage mediated GF release with gelatin microspheres(GMS, Chapter 3).
We found that HepHA successfully sequestered bFGF and the neurotrophic factor NGF,
as shown by increased L929 fibroblast proliferation and increased neurite length. In
addition, HepHA actively sequestered NGF during the course of the three-day
experiment. . In chapter 3, we made gelatin microspheres (GMS), filled GMS with NGF,
and confirmed degradation and NGF release only in the presence of collagenase. We
then electrospun NGF filled GMS with our unmodified HA fibers to determine GF
bioactivity, as well as the ability of GMS-fibers to release NGF in the presence of M1
conditioned media (M1CM). Though we saw that GMS tended to increase neurite lengths
without NGF included, possibly due to affinity binding of cytokines in M1CM, we also saw
increased neurite lengths and attachment in GMS-fibers with NGF.
By combining HepHA with GMS and PLGA-MS, we created a biomaterial
spatiotemporal system (STS) that delivers bFGF immediately, and BDNF in the presence
of M1 macrophages, with both GFs maintained by the hepHA nanofibers. The STS is
designed to mimic the GF release found in SCI. [7, 31, 46, 47]. We plan to test the STS
in an organotypic spinal cord (OSC) model compared to fibers with and without a single
GF.
OSCs can study cross-sectional or longitudinal slices of spinal cord (SC), both
having different uses; cross-sectional often studying the inflammatory response and cell
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survival[197-200], while longitudinal is used for evaluation of neural outgrowth, cell
survival, and lesion size and composition [201-204]. Most of the longitudinal studies used
commercially available inserts without biomaterials [201, 202, 204]. One longitudinal
model added a biomaterial on top of the spinal cord explants which were resting on a
custom well plate insert [203]. These published methods do not fit well with our STS
design; therefore, we have developed our own 3D printed insert that would allow for
inclusion of our biomaterial STS with longitudinal SC slices.
In this study we evaluated the STS with embryonic chick spinal cords, harvested
from E11-12 day eggs. After three days, 25% M1CM was added to simulate the
macrophage invasion expected in SCI. We compared the following groups after 1 week
of organotypic cell culture after injury: 1) methacrylated hyaluronic acid (MeHA)
nanofibers, 2) hepHA, 3) hepHA with PLGA-Microspheres with bFGF (hepHA+bFGF), 4)
hepHA with GMS filled with brain derived neurotrophic factor (hepHA+BDNF), and 5) the
complete STS comprised of hepHA with PLGA-MS+bFGF and GMS+BDNF.
We hypothesize that the STS group will perform best in terms of neurite extension
across the OSC injury gap and the OL presence within the OSC injury gap, as compared
to groups without GFs and groups with only one provided GF in a non-spatiotemporal
manner. We expect that HepHA+bFGF will affect the presence of OL, and the
HepHA+BDNF will affect the amount of neurite extension across the gap, but also realize
that that they are equally likely to affect both cell populations. Lastly, we expect that
MeHA and HepHA groups will have the least improvement in neurite crossing and OL
presence but will still provide a permissive growth environment for the model.
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Methods and Materials
Unless specified otherwise, materials were obtained from Thermofisher Scientific
(Waltham, MA). Gelatin microspheres were made as described in Chapter 3, (page 47)
Similarly, MeHA and HepHA were made as described in Chapter 2, (page 30).
PLGA Microsphere Emulsion Protocol
A water/oil/water double emulsion was performed to create PLGA-MS [3, 65]. The
inner phase consisted of deionized water with 0.04% polyvinyl alcohol (Sigma Aldrich, St.
Louis, MO) as a surfactant and 100µg/ml solubilized bFGF or BSA. The middle phase
was PLGA 50:50 dissolved in dichloromethane. The outer phase was deionized water
with 0.5% polyvinyl alcohol. 200 uL of the inner phase was added to 3 ml of the middle
phase and sonicated (VirSonic 100, Boston Laboratory, Woburn, MA) for about 30
seconds over ice. The resulting emulsion was then added to 40 mL of the outer phase
and vortexed for about 50 seconds. The final solution was then stirred in a beaker in a
fume hood for 2 hours. Once the solvent was allowed to evaporate, the suspension
containing the microspheres was spun down in a centrifuge set to 1000 rotations per
minute (RPM) for 5 min. The supernatant was then discarded, and the microspheres
resuspended in deionized water and centrifuged again to rinse. A total of three rinses are
done. After rinses, microspheres were frozen a -20C overnight. Microspheres were then
be briefly chilled in liquid nitrogen and lyophilized for 24 hours.
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Microsphere Diameters
PLGA-MS with BSA were imaged with scanning electron microscopy (SEM).
Diameters were measured with the MATLAB function imfindcircles().

The function

parameters were determined via trial and error on a sample image, such that the lighting
and contrast of the image set were considered, before batch processing five images of
PLGA-MS. The function, imfindcircles(), outputs the counted images and a spreadsheet.
In post-processing, counted images were checked for any blatant errors, and the
measurements from those errors were removed from the data.
Electrospinning Nanofibrous Mats with MS
MeHA electrospinning solution consisted of from 2% w/v MeHA, 3% w/v
polyethylene oxide, and 0.05% Irgacure 2595 photocrosslinker in DI H2O [28]. HepMA
was similar but included 1.5% MeHA and 0.5% hepMA. For HepHA with bFGF filled
PLGA-MS (HepHA+bFGF) and HepHA with BDNF filled GMS (HepHA+BDNF), 15 mg
microspheres were added per 1 ml electrospinning solution. HepHA with both sets of MS
(STS) included 15mg/ml microspheres for both PLGA-MS and GMS, leading to a total of
30mg/ml microspheres. MeHA and HepHA were electrospun at 22kV for 2 hours, hepHA
with microspheres were electrospun at 24kV for 2-3 hours, with extra care that the
collection mandrel temperature does not exceed 37˚C. All fibers were crosslinked using
a 365 nm wavelength UV light. Fibers containing GFs were stored in 4C with desiccant
to prevent as much premature hydration as possible while keeping GFs stable. Scanning
electron microscopy (SEM) was performed on gold sputtered fibers using a tungsten JSM
6510LV.
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M1 Macrophage Conditioned Media
Conditioned media was prepared as described in Chapter 3, following a published
protocol [174]. Briefly, CD14+ monocytes were isolated from peripheral blood samples,
and cultured in RPMI media supplemented with 10% fetal bovine serum for 2-4 hours
until adhered. 100U/ml GM-CSF was then added to the media and incubated for 24hours,
after which the media was replaced with complete RPMI containing 200U/ml GMCSF,
100ng/ml LPS, and 100ng/ml interferon-gamma (IFN-g) for M1 induction. The media was
replaced with fresh RPMI containing cytokines after 48 h and the cultures were further
incubated for 48 h. The culture supernatants (M0CM and M1CM) were collected, passed
through a 0.45 µm syringe filter and stored at -20C until use.
OSC Insert Trials
Several iterations of OSC experiments were performed before the insert design
and dissection method were finalized. These iterations can best be described as: Phase
0 – proof of concept, Phase 1 – alteration of commercial insert, Phase 2 – 3D printed
insert development, and Phase 3 – optimization of dissection and culture methods using
3D printed insert. Each phase will be described with methods, results, and considerations
for moving forward.
OSC Phase 0
There were several aspects we needed to prove possible before committing to
OSC culture. Most papers used McIlwain Tissue choppers to obtain 350-450um thick
slices of SC [197, 200, 202, 203, 205]. Additionally, there was barely any consistency in
media composition between papers. Base media varied between DMEM, DMEM:F12,
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and MEM with and without HEPES, as well as variation on serum types and percentages
[197, 200-202]. Our goals were to determine if thicker slices of SC could be used and
still obtain neurite extensions and connections, as well as to ascertain a media
composition and length of culture time that was possible.
Proof of concept OSC were performed on fibers electrospun onto glass coverslips,
for which small explants of spinal cords (SCs) were placed about 1mm apart (Figure 41, B and C), determined visually. SCs were dissected from day 11-12 chicken embryos
(Charles River, Roanoke, IL) in chilled Hanks’ balanced salt solution and kept on ice until
use. Bones, cartilage and meninges were carefully cleared from the spinal cords, 5mm
sections were cut from the lumbar region and then cut in half along the median fissure.
One SC provided for two OSC samples. Each OSC sample was further cut or pinched
transversely into two pieces to imitate a complete separation spinal cord injury. SC pieces
were placed on fibers one at a time, with evolving methods to reduce SC and fiber
destruction. OSCs were given 100-200ul of media initially and then added 100ul every

Figure 4-1 Phase 0 OSC schematic and immunofluorescence
A and B are both 100x magnification, with scale bars in the corner representing 500µm. C is the same area
as B, but at 200x magnification, scale bar is 250µm
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day for 3 days, balancing between drying out and causing the SCs to float. For the first
day, the media used for OSCs was composed of DMEM:F12 with 10% heat inactivated
horse serum (HIHS), 2 mM L-Glutamine, 0.6% B27, 50U/ml Pen-strep, and 12.6ng/ml
NGF. Subsequently, media was partially changed with: DMEM:F12 with 10% HIHS, 2mM
L-glutamine, 0.6% B27, and 50U/ml Pen-strep. Partial changes were performed every 23 days, taking utmost care to not detach SCs. After 2 weeks and 4 weeks, samples were
fixed with 4% paraformaldehyde for 30 min and immunostained with anti-neurofilament
neurofilament (N5389 Sigma Aldrich, St. Louis MO, 1:400), FITC conjugated secondary
antibody (A10684, 1:1000), and counterstained with DAPI.
Results and Future Considerations
This proof of concept was performed at the same time as dissociated dorsal root
ganglia (DRG) experiments reported in the previous chapter. The intent was to try to
culture SCs with our immediately available materials and then adjust as needed, based
on the available literature. Fortunately, the first set of parameters produced live SCs after
2 and 4 weeks of cell culture. Though we do not follow an exact recipe from a published
paper, we did move forward with the parameters that we found successful. The only
exception is that NGF was not added to the final formulation of OSC Media. The lack of
neurotrophic factors was one of the only consistent aspects of OSC media composition
between papers [197, 200-203, 205].
There were several factors that were found to aid OSC survival. One such factor
was always to keep the air-liquid interface below the SC explants. SCs that floated were
subsequently lost; sometimes due to the process of removing liquid from the well, and
other times due to apparent degradation. It seemed from this experiment that attachment
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was necessary for SC survival and that was only possible if the liquid height remained
low. In the surviving samples, neurite extensions could be clearly seen after 2 weeks
from one explant (Figure 4-1 A) and were found connecting two explants (Figure 4-1 B).
It should be noted that though the intention was to place the SC explants about 1mm
apart, the explants that had connecting neurites can be measured to be less than 500um
apart; this was not initially considered but will be important for later phases.
For Future OSC experiments, we decided to use a well plate insert to hold the SC
explants high enough for a substantial amount of media to be present. This would reduce
the variability in results due to daily evaluation and supplementation of media to individual
wells as they appeared to dry out. Additionally, it was decided that two weeks of OSC
culture was sufficient to find neurite extensions, as opposed to the alternate 4-week trial.
OSC Phase 1
Insert design
Phase 1 experiments were performed with a store-bought insert (PICM01250),
modified to allow a 5mm wide strip of nanofiber mats to be weaved through the
polytetrafluoroethylene film and superglued in place. Often, the superglue would wick up
the fibers and a new insert would need to be made. It was possible to maneuver spinal
cord explants onto the strips of fibers, however, the high walls of the inserts did require
finesse and a 10% gelatin mixture to help stabilize the spinal cords for transport and
placement. Changes to the dissection and placement method reflect the addition of the
gelatin stabilizer.
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Dissection, Placement, and Culture
A 10% gelatin solution was

A

produced and autoclaved at 121˚C
for 30min then stored at 4C until
use. Before spinal cords were
dissected, the 10% gelatin solution
was placed in a hot water bath 37˚C

B

to liquify. Dissected spinal cords
were transferred to a 35mm plate
with about 1ml of 10% gelatin, then
together chilled for at least 10 min
to solidify the gelatin. Rectangular
prisms containing spinal cords

C

were cut out of the gelatin, sliced as
done in Phase 0, and then placed
in insert as shown in Figure 4-2.
Tools were kept chilled for the
duration of the manipulation to
prevent the gelatin from melting.
The OSC inserts were allowed to Figure 4-2 Phase 1 Schematic and Immunofluorescence

A. Shows the side view of the store bough insert, from the

dry during the SC manipulation product documentation. B. Schematic of insert modification (top
view) with fibers woven through incisions made with a scalpel.

process, for otherwise the SC C) neurofilament is shown in green, cell nuclei in blue. Arrows
would shift as the gelatin melted.

indicate neurites or neurite clusters. Dotted line is the edge of
the SC explant, with the explant to the left of the line.
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The 1mm distance between SC explants was measured using a ruler placed under the
insert and confirming placement with a dissection scope. SCs were allowed to attach for
3-4 hours in the incubator without media, then gently rinsed once with PBS before adding
250ul of OSC Media (DMEM:F12, 10% heat-inactivated horse serum, 2 mM L-Glutamine,
0.6% B27, 50U/ml Pen-strep). After 3 days, M1CM was added as described previously.
OSCs were cultured for the total two weeks, while adding 150µl OSC Media with 25%
M1CM every 3-4 days to ensure the SCs did not dry out or begin to float or detach.
Immunofluorescence
Fixation and immunolabeling were performed as described in Phase 0 with a few
exceptions. For every rinse step, varying techniques were attempted to reduce the
likelihood of samples floating away. For the fixation step, this meant carefully removing
100-200ul of media, then adding 100-200ul of PBS and repeating 2-3 times before moving
on to adding fixative gradually in the same fashion. Immunolabeling was performed using
the same anti-neurofilament primary described in Phase 0 and 1, along with anti-GFAP
(RB087A0, 1:250) combined in the same step. Likewise, the FITC conjugated secondary
described previously was combined with Texas Red conjugated goat anti-rabbit
(A11012). Primary and secondary antibody solutions were added to wells until the point
at which the SCs began to float and incubated at 4C for 3 days (primaries) and 2 days
(secondaries). The antibody incubation times were initially set at overnight for primary
antibodies and 2 hours at room temperature for secondary antibodies but were
systematically increased until neurites could be seen.
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Results and Future Considerations
Ultimately, there were no distinguishable neurite extensions crossing the gap after
two weeks (Figure 4-2), even with increased incubation time with primary and secondary
antibodies. This may have been due to the gelatin stabilizer not being completely washed
off and thus trapping the neurites, or from excess superglue that may have found its way
into the cell culture media harming the culture environment. The anti-GFAP label did not
show any noticeable GFAP positive cells, though it is possible that the gelatin or
superglue presence also affected the astrocyte presence or lack thereof. Additionally,
when it came time to image, the inserts proved to inhibit our ability to focus on the
neurites, making quantification of neurites impossible. This could be remedied by cutting
the fibers out of the inserts and removing the polytetrafluoroethylene film, but this often
destroyed the sample.
Based on these results, it was determined that the final OSC insert design needed
to: 1) not rely on superglue, 2) have low walls to remove the need to stabilize the SCs for
transport with gelatin, and 3) easily become flat with no additional material layer for the
sake of obtaining crisp images.
OSC Phase 2
3D printed inserts
Inserts were created in order to hold the fibers and dissected spinal cords about
2mm high, in order to allow spinal cords to rest at the air-liquid interface while still allowing
for 400-500µl of media to be available. Previous trials showed that spinal cords would
float and detach from fibers if the media levels were too high, even after culturing for two
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Figure 4-3 Schematic of Phase 3 3D printed insert and dissection example
SC explants are placed about 1mm apart in the final OSC setup, with the blue highlighted marker indicating
a 1mm width.

weeks. Several iterations were tested before settling on the final design shown in Figure
4-3. For this final design, 1.75mm clear PLA filament was used in a Raise3D Pro2 Plus
(Raise3D, Irvine, CA), using Ultra high resolution: 0.1 mm first layer, 0.05 layer height,
shells = 1. Inserts consisted of a top piece (blue), bottom piece (orange), and a separate
stand (gray), to hold the insert 2mm high. Fiber mats, indicated in green in Figure 4-3,
were cut into 1.25 x 1.5 cm rectangles and then sandwiched between the top and bottom
pieces. Pegs on the bottom piece poke through the fibers and insert into the top piece to
hold the fibers in place. An additional part was printed that slotted into the stand in order
to aid in removing the OSC insert from the well plate.
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Dissection, Placement, and Culture
SCs were dissected similarly to the previously described methods with some
exceptions. SC pieces were placed one piece at time onto the fibers, leaving a 1mm gap
as determined visually by comparison with a 1mm indicator on the 3D printed insert. After
placement, 500ul of OSC media was added per well, such that the fibers were just barely
in contact with the fluid. OSC media consisted of DMEM:F12, 2 mM L-Glutamine, 0.6%
B27, 50U/ml Pen-strep, supplemented with 10% heat-inactivated horse serum (New
Zealand Origin, 26050088). After 3 days of culture, OSC media in each well was
replenished to 500ul, including 125ul of M1 macrophage conditioned media. One week
after dissection, additional media was added, maintaining the 25% M1 conditioned media
ratio. Two weeks after dissection, samples were fixed with 4% paraformaldehyde.
Immunofluorescence
Several methods were tested with regards to rinsing, fixing, and immunolabeling
in order to preserve samples without breaking the fibers or losing the SCs. The best
method was determined to be the following:
OSCs were lifted out of the well, adding liquid if necessary, to prevent fiber
breakage. The insert was moved from the stand to PBS covered glass slides and fixed
with 4% paraformaldehyde for 30 min. OSCs were blocked with 10% normal goat serum
and then labeled with primary antibodies: anti-neurofilament (N5389 Sigma Aldrich, St.
Louis MO, 1:400) and anti-GFAP (RB087A0, 1:250) for three days in humid chambers at
4C. Corresponding secondary antibodies were goat anti-mouse (A10684) and goat antirabbit (A11012), incubated in humid chambers at 4C for one day. OSCs were also
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counterstained with DAPI. After staining, samples were kept hydrated with PBS in humid
chambers and stored at 4C until they were completely imaged.
Imaging and Image Processing
Nikon NS elements software was used for imaging. Samples were imaged in an
x-y grid formation to cover the injury gap, with a 50µm overlap between images to aid with
stitching; this resulted in 24 to 45 images per sample. Each image was a z-series image,
such that multiple pictures were taken at different focuses (eg. z height) for each location
in the x-y grid. Z height values for each image was determined based on the highest and
lowest locations where a piece of the SC explant or what could be considered a neurite
was identifiable. The distance between z values was variable between 5 and 8 microns
and changed such that a minimum of five images were taken for the z-series at each x-y
location. Z-series were aligned and focus stacked using the open source code Enfuse.
Once images were focus stacked, Image J Fuji was used to stitch the grid of images
together. Some issues arise if there are not enough control points (pixels or groups of
pixels that are consistent between images) between the z-series images or within the
overlaps for stitching. This can require removing images from the z-series, as well as
manually stitching the x-y grid.
Results and Future Considerations
Without a support material such as the polytetrafluoroethylene in the commercial
inserts, the fibers were often pulled by the surface tension of the liquid in the cell culture
well. With media evaporation during the experiment and the multiple rinses required for
fixation and immunolabeling, fibers often stretched to breaking. Additionally, after the
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fibers had stretched, adding media or other liquids to prevent breakage often caused the
SCs float. Due to this, a minor addition was made to the insert’s stand. The triangular
shapes on the stand seen in Figure 4-3 were added to help support the fibers such that
they could withstand forces from surface tension each time liquid was removed or
evaporated. This was addressed during the initial designs of the 3D printed insert and
are worth noting, but not substantial enough to be given its own phase. It should be
emphasized however, that a major concern with the 3D printed insert was fiber stability.
This, in addition to preventing the SCs from floating, were major factors in determining
processing methods.
The OSC culture lasted for two weeks, however one sample was fixed and
prepared at one week. This was to troubleshoot any issues with fixation, immunolabeling,
imaging and quantification prior to the main batch of samples. At one week, the fibers
did not break during
fixation

or

the

immunolabeling
process and were
successfully
transferred
glass

to

a

microscope

slide for imaging.
The fibers were cut
out of the insert and
placed

under

a

Figure 4-4 OSC Phase 2 sample at 1 week
Neurites are labeled with anti-neurofilament (green), nuclei with DAPI (blue).
Arrows indicate neurites extending from the SC, a portion of which is visible at
the top of the image.
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glass coverslip with 50% Glycerol for imaging. Neurites could be seen extending from
SC explants (Figure 4-4), however the process of cutting the fibers out of the insert was
initially deemed too time intensive and destructive to the sample. This guided the decision
to keep the samples in the inserts and hydrated in PBS until completely imaged for the
rest of Phase 2 samples.
Initially, SCs were fixed prior to moving to a glass coverslip with the idea that fixed
samples would be stronger for transport, and since the fibers did not break with the oneweek sample, it seemed safe to performed on the samples as a batch. However, this
destroyed the two-week samples. The fibers became very brittle after fixation and seemed
fixed to the PLA stand. During the second set of experiments, many methods and
manipulations were tried before finding that the fibers could withstand being moved before
being fixed. These remaining samples were then immunolabeled on the glass coverslips
similar to how tissue slices would be, though the insert was still present. Fibers were kept
hydrated with PBS and images could be obtained that focused on nerve bundles. As
individual neurites were seen as early as one week after dissection (Figure 4-4) and that
the processing methods at two weeks introduced unforeseen complications, we decided
to perform Phase 3 OSC with one week of culture as opposed to two. This is also
supported in literature that shows nerve regrowth can be significantly different after just 7
days [201, 203].
We planned to use the final stack focused and stitched image (See Figure 4-5 for
an example image) to quantify the percentage of neurite crossing, as well as the relative
number of activated astrocytes. However, even with z-stacking, it is proving infeasible to
keep track of the individual neurites across such a large gap, particularly when they
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tended to form bundles of cellular material. The number of images necessary varied
widely from sample to sample and from spot to spot within a single sample. One sample
needed a grid including 24 image locations while another needed a grid including 45
image locations to fully capture the area between the SC explants. Considering that each

500um

Figure 4-5 Example of stack-focused images, stitched together based on their x-y grid position.
GFAP is indicated by red, anti-neurofilament by green, and nuclei by the blue DAPI stain. These fibers
included PLGA microspheres filled with basic fibroblast growth factor, which auto fluoresce (see white
arrow head). The overexposed blue/green areas (outlined) are the spinal cord explants. Scale bar in top
left corner is 500um. The gap between the two pieces of spinal cord measures about 2 mm.
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one of those locations included data for at least five and up to 55 images for the z-stack,
it became a time consuming and data heavy endeavor; one sample’s worth of data was
15.2GB of images. Even with the effort to capture the injury gap with so much detail,
there was no feasible way to keep track of neurites such that neurite crossing could be
measured. After returning to the literature and considering our previous proof of concept
images (Figure 4-1, B and C), we determined that an injury gap of around 500µm or less
would be better suited for measuring neurite crossing [203, 204].
Additionally, the anti-GFAP immunolabel gave faint glows rather than distinct
morphologies, in both OSC samples and astrocytes isolated from chick spinal cords. As
such, the original plan to count the number of reactive astrocytes was no longer feasible.
OLs were our first choice for what to quantify within the OSC samples, however the wellknown MBP and MOG antibodies were not listed as reactive in chicken and often used
for mouse. Due to this, we decided to use anti-GFAP because it was an established
astrocyte immunolabel with listed reactivity in chicken. However, considering the results
we found in this phase, we returned to the search for an appropriate immunolabel for OLs,
with the specific criteria: raised in rabbit and reactive with chicken, rated for
immunofluorescence, and known to be in E10-11 and older chick spinal cords. OLs have
a very spatiotemporal life cycle within the chick spinal cord [206-209], shifting from OPC
prior to embryonic day 5 (E5), to OL progenitor at E5, to full OL at E8, each stage with
different markers [206]. Further after E8, there are different labels that work better at
different days and locations; myelin oligodendrocyte specific protein is found in E19 and
adult chicken retinas [210], while anti-myelin PLP is highly expressed in the white matter
at E11 but lower at E16 in the gray matter of a cross-sectional chick spinal cord [211].
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Ultimately, Olig2 was the best choice as it was found at E10 with increasing amounts until
E17.5, throughout the spinal cord [209, 212], and matched the specific criteria.
Based on these and previous OSC data, we decided to move forward with a oneweek culture time instead of two-week, with a smaller injury gap, and with anti-olig2
antibody label instead of GFAP labeling.
Phase 3 OSC Trial – Finalized Method
Dissection and OSC culture
The entire, finalized method is as follows:
Spinal cords were dissected from day 11-12 chicken embryos (Charles River,
Roanoke, IL) in chilled Hanks’ balanced salt
solution and kept on ice until use. A least 4 OSCs
per group were cultured over five sets of one-week
long experiments. Bones, cartilage and meninges
were carefully cleared from the spinal cords, 4mm
sections were cut from the lumbar region and then
cut in half longitudinally. One spinal cord provided
for two OSC samples. Spinal cord sections were cut
transversely, then placed one piece at time onto the Figure 4-6 Phase 3 OSC - SC explant
fibers, such that SCs were allowed to just barely
touch or have the smallest possible gap. A clear

placement
SC explants were placed with as small a gap
as possible while still showing a distinct
separation.

line between explants was confirmed using the dissection microscope (Figure 4-6) .
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After placement, 500ul of OSC media was added per well, such that the fibers were
just barely in contact with the fluid. OSC media consisted of DMEM:F12, 2 mM LGlutamine, 0.6% B27, 50U/ml Pen-strep, supplemented with 10% heat-inactivated horse
serum. After 3 days of culture, OSC media in each well was replenished to 500ul,
including 125ul of M1CM. After one week, OSCs were moved to glass slides, fixed with
4% paraformaldehyde, then labeled with primary antibodies: anti-neurofilament (N5389
Sigma Aldrich, St. Louis MO, 1:400) and anti-Olig2 (AB9610, 1:1000, EMD Millipore) for
5 days at 4˚C. Corresponding secondary antibodies were goat anti-mouse (A10684) and
goat anti-rabbit (A11012), incubated overnight at 4˚C. OSCs were counterstained with
DAPI.
Imaging and Image Processing
Initially, images were obtained while the samples were still within the inserts,
however a new method of removing the inserts was found that allowed for consistent
sample retention.

As such, samples were removed carefully from inserts, labeled as

necessary, and then mounted with 50% glycerol.
Images encompassing the entire SC and gap region were obtained with the 4x
objective, while the 20x objective was used for just the gap region to visualize OLs. Each
20x objective image was a z-series image, such that multiple pictures were taken at
different focuses (eg. z height) for each location imaged in the SC gap. Z height values
for each image was determined based on the highest and lowest locations where a piece
of the SC explant or OLs were clearly visible. The distance between z values was 22.5µm. Z-series were aligned, and focus stacked using the open source code Enfuse.
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Once each 20x image was focus stacked, then free Hugin panorama software was used
to stitch images into one, large, high resolution image of the injury gap.
Injury gap percent recovery
As neurites were not always visible in thicker segments of the samples, a
different approach was used to quantify OSC reconnection. Low magnification (4x
objective) images were taken to include the injury site, then SC outlines were identified
by separating the blue (DAPI) channel and adjusting the threshold until the smoothest
edges were obtained. A region of interest (ROI) representing the SCI gap was made in
ImageJ; when the top and bottom SC outlines started to turn away from an otherwise
straight edge, that point was considered the beginning of the injury gap and an ROI was
made based on the four corners of the injury gap. The ROI outline was then transferred
to the green channel, where thresholding was performed again to capture the green
areas within the gap. A binary image was created and measured the percentage of the
Figure 4-7: Example
SC, Gap, and percent
gap recovery image
processing.

B

A

C

D

A) 4x image of OSC,
with SC regions outlined
in white, and the defined
injury gap outlined in
red. B) A binary image
of the blue (DAPI)
channel, used to define
the SC regions. C) The
gap alone in a full color
image, enlarged to show
contrast with D) the
binary image of the
green channel, with
thresholding performed
to catch green areas
with minimal
background noise.
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binary image with black pixels (ie, the green space). An example image of each of the
steps is provided in Figure 4-7. Number of completely reconnected OSC samples was
determined based on having a 100% gap recovery via this method.
Oligodendrocyte Number and Density
High resolution images of the gap were taken (20x objective), then stitched with
Hugin software as described. The gap ROI defined on the 4x images were used to identify
where to count OLs. The number of Olig2 positive nuclei were counted in each gap ROI
then averaged and reported as number of OLs per gap. Additionally, number of OLs per
gap were normalized by area of the gap to obtain the OL density for that OSC sample.
The average OL density was also reported. In cases where the SCs were completely
reconnected, this analysis was not performed. If there was any question about the Olig2
positive nuclei being one or two cells, it was counted as one. Cells with Olig2 present in
the cell cytoplasm and nuclei were also counted.
Statistics
R Project (R version 3.5.1, 7-2-1018) was used for statistical analysis. Unless
otherwise specified, a one-way ANOVA was performed, with Bonferroni adjusted multiple
comparisons post hoc when appropriate.
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Final Results
PLGA-MS and Fibers characterization
SEM images show smooth PLGA-MS (Figure 4-8) while quantification via matlab
found the average diameter to be 39 ±14 µm. Similarly, SEM showed smooth fibers
across all groups, with both GMS and PLGA-MS incorporated where appropriate (Figure
4-9). GMS and PLGA-MS are indistinguishable in SEM images, but under brightfield
microscopy, both microspheres were confirmed to be present (Figure 4-10).

Figure 4-8 PLGA-MS SEM and characterization
A. SEM of PLGA-MS, scale bar is 100µm B. Descriptive data, where MS is the total number of
microspheres counted out of 5 images
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A

B

C

D

E

F

Figure 4-9 SEM images of nanofiber mats
A) MeHA, B) HepHA, C) HepHA+bFGF, D) HepHA+BDNF, E) STS. A-E are the same magnification, scale
bar in A is 10µm. F) STS at lower magnification to show distribution of MS. Scale bar is 100µm.

Figure 4-10 Comparison of STS in SEM and Brightfield microscopy
A) SEM image of STS, PLGA-MS and GMS are indistinguishable. B) Brightfield image of STS in OSC culture,
GMS are translucent while PLGA-MS are dark.
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OSC Immunofluorescence
Total number of samples per group and the number of completely reconnected
samples per group were determined and reported in Table 4-1. Example images of entire
OSCs at low magnification are shown in Figure 4-11. Average percent gap recovery was
highest in STS, with HepHA and HepHA+BDNF showing the next highest percent
recoveries. There was no significant difference between groups. Images taken at 20x
magnification were used to visualize OLs within the nerve injury gap. Average number of
OLs per gap and average OL density (per mm2) are reported in Table 4-1. An example
high magnification, stitched image of STS as well as one location within the stitched image
is shown in Figure 4-12. A larger example image of each group is provided in Appendix
D.

Table 4-1 OSC Immunofluorescent Analysis
MeHA

HepHA

HepHA
+bFGF

HepHA
+BNDF

STS

N

6

5

5

4

4

No. completely
reconnected

1

1

1

1

0

Average Gap
Recovery (%)

74.2 ±20.7

82.0 ±19.7

66.0 ±28.9

83.7 ±27.5

86.6 ±4.0

Average No.
OLs per gap

28.3 ±6.8

81.0 ±29.5

37.5 ±17.4

51.7 ±14.6

125.0 ±92.7

Average OL
density (mm2)

31.5 ±13.8

134.7 ±101.6

48.0 ±26.1

98.7 ±41.1

122.1 ±68.9

Averages represent the mean ± standard deviation. Abbreviations: No., number; OLs,
Oligodendrocytes; mm, millimeter.
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A

B

C

D

E

Figure 4-12 Low magnification
example images of injury gap in
OSCs
A)MeHA, B) HepHA, C)
HepHA+bFGF, D) HepHA+BNDF,
E) STS. All are same
magnification, scale bar in A is
200µm

Figure 4-11 High resolution OSC gap example for
Oligodendrocyte cell count
A) STS stitched image of entire gap, with the gap outlined by a
yellow box. B) Single 200x image (20x objective) from the gap,
shown here to highlight Olig2 positive nuclei (yellow arrows).
The large red spheres (green arrow) are GMS, which auto
fluoresce brightly 594nm (red channel).
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Average number of OLs per gap were highest in STS, with the next highest being
HepHA. ANOVA produced a p-value of 0.07, which did not meet the 0.05 threshold to
reject the null hypothesis of equal means. Post-hoc analysis was performed to evaluate
trends: STS was least similar to MeHA (p = 0.10) and HepHA+bFGF (p = 0.18). HepHA
had the highest OL density, followed by STS and HepHA+BDNF, with no statistical
differences between all groups.
Discussion
SCI is a complex wound environment that varies from patient to patient and is often
studied in terms of quantified motor function and sensory ability regained over time. For
animal studies, the typical model is to induce a SCI in rodent models, apply the proposed
intervention, and then care for the rats while measuring motor and sensory abilities over
time [102, 106, 117, 213]. This can include treating pressure sores as they develop,
helping rats with urination and bowel movements, and compensating for thermal
regulation when necessary [213]. Though measures are in place to keep the process as
humane as possible, there is still a large push for alternatives that not only reduce, reuse,
and recycle the number of animals used but also allow for a more in-depth and controlled
look at cellular and chemical interactions within the injury environment [31, 203, 214].
Organotypic spinal cord (OSC) models are an ex vivo alternative, with a large reduction
of cost and time per experiment, which keeps the tissue structure intact and undergoes
similar primary and secondary damage seen in SCI [202, 204].
OSCs have been produced using chick, mouse, or rat spinal cords, dissected and
sliced into transverse pieces 350-500um thick, and cultured on well plate inserts [198200, 205, 215, 216] or in matrigel [197]. Longitudinal OSCs are less common, but still
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have found success [201-204]. Groups that sliced their spinal cords into cross-sections
quantified the glial response to M1 and M2 macrophage conditioned media [197],
performed cellular transplants [198, 199], or introduced pharmacological intervention
[200]. The longitudinal organotypic model focused more on axonal growth across a lesion
made transversely to the section [201, 203] and evaluation of primary and secondary SCI
markers [202, 204]. As such, the longitudinal model is most relevant to our research
regarding an implantable biomaterial to increase neuronal reconnection after SCI.
In this chapter, we combined PLGA-MS used previously in the lab [3, 65], with
HepHA fibers developed in chapter 2, and the enzymatically degraded GMS from chapter
3 to create a spatiotemporal growth factor release biomaterial system, electrospun to form
nanofibers and guide neurons via mechanical and timed biochemical cues. We tested
the STS in a 3D printed OSC insert, designed to accommodate biomaterials and aid in
SC placement and maintenance.
We initially had planned to quantify neurite crossing based on images of OSC
injury gaps in the literature [201, 202]. In the published system, a semi quantitative
approach was used to score each OSC injury gap based on the number of neurites on
each side of the gap versus within the gap [201]. We had thought to attempt a fully
quantified neurite crossing number using image thresholding and DiameterJ plugins,
similar to how we measured fiber diameter and alignment in Chapters 2 and 3. However,
we found very few individual neurites in our OSC samples. Even with applying glycerol
and glass coverslips, imaging with the coverslip facing the objective, we still could not see
all the individual neurites. Instead we only captured an indistinct green glow with the
occasional bright, crisp neurite within. This could be due to the tissue samples thickness.
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Other OSC models use a McIlwain tissue chopper or imbedded their SCs in gelatin to be
cut with a vibratome to achieve 350-450µm thin slices of SC per OSC sample [197, 199,
200, 202, 203, 205]. We had hoped to avoid the additional step and equipment; our proof
of concept with whole SC hemi sections did show surviving SCs with neurite outgrowth,
visualized with anti-neurofilament. However, in the later phases of the OSC experiments,
larger SC explants with more connecting tissue were present than in the initial proof of
concept sample. It is well known that the thicker the tissue sample being imaged, the
more autofluorescence is present, particularly in central nervous tissue [217-219]. We
ultimately decided that a percentage of green immunolabeled tissue within a defined gap
region would be an appropriate replacement metric. This is also a relevant method for in
vivo studies, for both SCI [220] and peripheral nerve injury [99].
We did not statistically confirm that the STS improved neurite reconnection
compared to groups without GFs or groups without spatiotemporally delivered, single
GFs. However, we find the high average percent gap recovery and low standard deviation
for STS to be promising. Future studies could use the same metric with a higher sample
size; a power analysis with the current data suggests that a sample size of 8 could show
a difference between STS and MeHA, for example. Alternatively, future studies could
attempt a more traditional approach with slicing samples post fixation to avoid the
autofluorescence issue, or by using a confocal microscope for a 3D image of the whole
tissue [221, 222].
We reported both the average number of OLs per gap and the average OL cell
density (per mm2). Both numbers gave interesting but separate results. STS had the
highest number of OLs per gap, though the ANOVA did not show significance to the
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required α<0.05. However, the trend that STS may be different from MeHA and
HepHA+bFGF might be confirmed with a higher sample size in future studies. We find it
interesting that the group with bFGF alone, the GF picked for its protective properties for
OLs had one of the lower values of OL presence. For this we consider the OPC and OL
development timeline and our choice in immunolabel.
The reasoning behind using anti-Olig2 was described earlier (OSC phase 2, page
84), however it worth discussing again in the context of OPCs and OLs. OPCs have been
a somewhat controversial cell, with multiple name changes, and ultimately have been
listed as a multipotent stem like cell in the central nervous system [223]. There are several
immunolabels that can be used to identify OPCs and OLs at various timepoints. Both OLs
and OPCs can produce Olig2 in the cell nuclei, and both are important for SCI recovery
[212, 223-225]. Our decision to use Olig2 was based on antibody availability, as well as
literature showing the presence of Olig2+ OL in chick embryos from E8-E17.5 [212].
However, it may be more useful to look for OPC and OL specific immunolabels, as bFGF
has been shown to specifically increase OPC proliferation and then differentiation to OLs
in SCI [223]. It is conceivable that there is more OPC activity in the bFGF groups that are
not being visualized by Olig2. However there is also considerable evidence to suggest
that OPCs also produce Olig2, and even that OPCs with Olig2 are specifically responsible
for increased myelination [225-228]. So though there may be merit to distinguishing
between OPCs and OLs, it may also be reasonable to consider that Olig2+ cells are still
a valid metric for determining regeneration within SCI.
We also reported OL density, with the intent to separate potential gap size bias
from the OL number data. In the literature, there are a few groups that quantify OPC
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density, though usually in the context of OPC to OL differentiation at a particular density
[225, 229]. We found that HepHA had the highest average OL density of 134.7 OLs per
mm2, with STS showing as a close second at 122.1 mm2, HepHA+BDNF as third highest
at 98.7 OLs per mm2, while MeHA and HepHA+bFGF were lower than 50 OLs per mm2.
Though these results are not significant, this metric may be useful in conjunction with
future studies that evaluate OPC versus OL presence, and perhaps quantify the amount
of differentiation that is occurring.

It could be beneficial for future OSC studies to

characterize OPCs with multiple antibodies, such as anti-PDFGRα and PLP to gain a
better picture of the OPC to OL transition [206, 228].
One interesting result in all three metrics performed was that HepHA was
competitive with STS. Initially, we hypothesized that all GF groups would have enhanced
neurite regeneration and OL presence than the MeHA and HepHA fibers alone. However,
it is possible that heparin alone, ready to sequester any available GF or cytokine, may be
useful in SCI. We have seen in Chapter 2 that heparin can actively sequester from the
provided media and possibly increase attachment even without added GFs [180]. We
have also seen in Chapter 3 that molecules in CM such as IL-6 could be sequestered and
contribute to neuronal outgrowth. We also know that there are many, many beneficial
factors that are released within the SCI [7, 9, 46, 47], including those that increase OPC
proliferation and OL remyelination [223, 225]. It would be very reasonable to assume that
the available heparin could sequester the available biomolecules in a spatiotemporal
profile without the need for additional GF delivery. An immediate next step to evaluate
this, in future repeats of the OSC model, would be to collect media at multiple timepoints
to perform a cytokine and GF analysis and determine what is present at specific times.
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In this chapter, we combined the materials from chapter 2 and chapter 3 into a
completed system, in order to deliver growth factors in a way matching the native SCI
environment. We also underwent an arduous process to be able to evaluate this system
within a biomaterial-focused OSC model. The overall goal was to test if a spatiotemporal
release of bFGF and BDNF would have a larger effect on SCI neurite reconnection and
oligodendrocyte presence as compared to either GF delivered alone or the fibers by
themselves. We found that the STS did have increased percent gap recovery compared
to the other groups, though not significantly so. Additionally, we found that STS had the
highest number of OLs per gap, but that HepHA had the highest OL density. Though
none of these results were statistically significant, there were several interesting trends
that are worth further investigation.
There are two useful directions that this research could go in. First, to propel the
concept of spatiotemporal delivery in a SCI environment, and second to encourage OSC
for use in ex vivo studies regarding SCI. With the prior, a potential next step would be to
test the STS in an in vivo study with a reduced number of animals based on these results,
furthering the advancement toward a viable SCI treatment option.

With the second

direction, the embryonic chick OSC could be characterized and used to model the SCI
timeline, enlightening scientists and engineers about the processes and factor expression
during the event. This model is particularly useful in providing about 500ul per sample of
media that could be collected and analyzed, while still providing the air-liquid interface
needed for OSC survival. And as a combinatory approach, a conduit structure could be
made and tested using a slightly modified insert, and a more traditional histological
analysis could be performed on slices of OSC samples. These research directions would
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be worthwhile to advance SCI understanding and treatment, such that a gold standard
treatment could be finally be determined for such an impactful injury event.
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS
This thesis set out to determine a biomaterial system to spatiotemporally deliver
GFs to mimic the in vivo wound response in SCI, and to evaluate such a system in a SCI
environment. More specifically, we hypothesized that immediate delivery of bFGF and
delayed delivery of BDNF would enhance SCI regeneration by increasing OL survival,
and therefore OL presence, in the injury gap as well as increasing neurite extension and
reconnection across the injury gap.
In Chapter 2 we modified heparin, in the form of sodium heparin salt from porcine
intestinal mucosa, to be crosslinked to MeHA, an established biomaterial that can be
electrospun for nerve tissue engineering applications. Heparin is well known for
sequestering GFs and maintaining GF activity in vivo, counteracting short GF half-lives
[119-121, 130, 139, 153, 155, 189, 230-232]. This property is useful particularly in injury
environments, where the inflammation response is actively clearing the area of debris
[152, 162]. We modified heparin in two ways, via methacrylation and thiolation, and tested
both methods against MeHA in in vitro studies. We evaluated L929 fibroblast proliferation
and dissociated chick DRG neurite extension. These two tests were used to show
sequestration of bFGF, a GF considered to protect OLs from mass cell death that occurs
immediately after SCI, and NGF, a neurotrophic factor with similar heparin binding
properties to BNDF as well as known quantifiable effects on chick neurons. We
successfully modified HepMAHA (HepHA) and HepSHHA and found that HepMAHA
(HepHA) was superior to HepSHHA in both bFGF and NGF sequestration.
Concurrently, in Chapter 3 we recreated GMS to provide a delayed release of
BDNF via enzymatic degradation of gelatin in the presence of macrophages. We
characterized GMS size and measured NGF release, again using NGF as a proxy, in the
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presence of chromatographically purified collagenase. Further, we electrospun NGF
containing GMS within MeHA nanofibers (GMSF) to be cultured with chick neurons, with
and without macrophage conditioned media. We found that the GMS degrade in the
presence of collagenase and release NGF only enzymatically, as opposed to diffusion
from GMS.

Further we showed increased neurite lengths with GMSF+NGF in M1

macrophage conditioned media (M1CM), though we were also surprised to find that
GMSF without NGF also increased neurite lengths in M1CM, indicating a positive effect
of degraded gelatin and M1CM on neurite outgrowth.
After creating HepHA in Chapter 2 and confirming GMS macrophage mediated GF
release in Chapter 3, the two were combined in Chapter 4 with previously established
PLGA-MS [65] filled with bFGF, to build the completed STS. The STS would provide
bFGF immediately due to hydrolytic degradation of PLGA-MS, BDNF delayed due to
enzymatic degradation triggered by M1 macrophages within the immune response after
injury, with both GFs held in place by aligned HepHA nanofibers. A biomaterial-focused
OSC insert was designed, 3D printed, and used to test the STS against MeHA and HepHA
nanofibers, as well as HepHA with either bFGF or BDNF. All groups would be given an
injury of less than 1mm and have M1CM added after three days to simulate the SCI
immune response peak. Percent gap recovery and OL number per gap and OL density
(per mm2) were quantified. STS had the highest average percent gap recovery and the
highest average OL number per gap, though there was no statistical difference between
groups. HepHA had the highest OL density, with STS and hepHA+BDNF competing, but
no statistical difference was found.
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Future Directions
I believe that we, as a scientific community, are on the cusp of a breakthrough
regarding SCI regeneration. Five years ago, the word “spatiotemporal” had not become
standard lexicon for timed delivery of GFs. Now, spatiotemporal GF delivery is considered
a vital strategy [31], and biomaterials including heparin are showing in more published
papers [122, 155, 156, 158, 180]. Additionally, several excellent SCI related review
papers have been published within the last year or two pertaining to: biomaterials, clinical
and preclinical trial results, updated prevalence statistics, heparin binding as therapeutic
targets,

peripheral

nerve

strategies

for

SCI,

injectable

hydrogels,

and

oligodendrogliogenesis within SCI [6, 9, 28, 51, 228, 230, 233, 234]. It is energizing to
see the research from the last 20-30 years are beginning to coalesce into several good
review papers. The next few years will have better organized resources for developing
the next best strategy, which may well include heparin biomaterials and spatiotemporal
GF release.
While SCI regeneration strategies seem to be on the cusp of a breakthrough,
organotypic explant culture seems to be on the rise. With the research from the 1990’s
not successfully translating to human clinical trials, there’s push to reconsider the animal
model [214]. Organ-on-a-chip and Organotypic explant culture are promising ways to
follow the third “R” and replace animal models entirely. Organ-on-a-chip has shown
promising results, particularly when mimicking pulsatile flow, mechanical stretch, and
controlled biochemical concentration gradients, which are useful for tissues such as liver,
lung, intestinal linings and heart [235-238]. However, many of these models incorporate
distinct cell populations prepared in vitro prior to the creation of the microfluidic device,
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and have complex fabrication procedures [235]. Organotypic explant cultures can provide
a more complex environment with multiple cell types received directly from a tissue
source, however, many are limited to therapeutic agent and cellular, co-culture
applications [199, 202, 203, 205, 215].
This thesis provided a way to test a biomaterial system within an OSC insert,
successfully culturing SC explants with multiple cell types cultured together and visualized
via immunohistology. However, there is much to be explored with this setup. Many OSC
papers spend a considerable amount of time validating their system as a means to
accurately represent the immune response and injury response timeline [203, 204]. We
wanted to show that the STS enhanced the neurite reconnection as compared to MeHA
alone and with single GFs, and so did not spend the time to validate the presence of all
SCI response markers or to validate a matching timeline.

This could certainly be

performed. In addition to accommodating biomaterials, our OSC insert design allows for
500ul of media to reside in the well without causing the SC to become unattached. This
could allow sera evaluation to be performed with fewer samples and higher volume. This
along with multiple immunolabeling protocols could easily characterize this OSC
environment and timeline to be compared with SCI literature. The OSC insert could also
have several uses outside of this research’s specific use.

Any thin film or matted

biomaterial could be evaluated with this insert, as well as any tissue that benefits from an
air-liquid interface sung as lung, cerebral tissue, or gastrointestinal linings [239-241].
Since biomaterial-based inserts are typically custom designed, as done in this thesis and
by Weightman et al [203], it could be beneficial to mass produce the insert design for
other biomaterials groups to make use of.
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Several interesting results were gained over the course of this thesis. For one,
heparin may have an effect on attachment and cell survival that is separate from the effect
of sequestering GFs, based on the data in Chapter 2. Additionally, based on Chapter 4,
it is possible that HepHA by itself can perform just as well as the STS, perhaps due to the
ability to sequester GFs that are naturally released in the injury environment, without the
need for exogenous supplementation. HepHA by itself may be a valuable biomaterial,
easily produced and packaged for versatile use. Another interesting result was that
gelatin may also have some ability to sequester GFs, based on the data and discussion
from Chapter 3. Though we were not concerned with the idea of running out of heparin
binding locations by the time BDNF was released, it was comforting to find that gelatin
may have counteracted such a scenario.

Lastly, though there was no significant

difference between groups, the STS did have the highest averages for percent gap
recovery and OL number per gap. The STS is worth further investigation, be it in
additional OSC trials, or perhaps with a conduit shaped OSC model.
Microspheres and heparin are both versatile materials that can be modified for a
variety of applications. PLGA-MS can be filled with any water-soluble protein or molecule.
GMS can be loaded with any positively charged molecule. Heparin is known to bind to a
variety of growth factors and support molecules [121, 128]. HA is a non-immunogenic
material, which is vital for implantation, and can be modified for a variety of uses [50, 100,
242-244]. MeHA can be used as electrospun nanofibers, as listed in this thesis, or as a
hydrogel [3, 65, 137, 180, 242]. This could be particularly useful in crush SCI injuries
where there is no clear penetration of the damaged tissue [9]. Considering all these
things, it is very possible to find different but appropriate GFs or therapeutic agents for
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most tissues and injuries. Even within SCI, there are many directions this system could
take.
A therapeutic agent such as, Methylprednisolone (MD) or Riluzole, could be used
in GMS. MD provided via bolus injection has been shown to negatively impact patients
with SCI, due to the systemic immunosuppression it provides [7, 24]. However, in low,
directed doses, it has potential to reduce the inflammation responsible for support cell
death and tissue necrosis [245]. Within GMS, the release of MD would be modulated by
the M1 macrophage response. Experimentation is needed, but it is possible that MD
released from GMS and the M1 macrophage immune response would keep one another
in check. Otherwise, it is possible to provide an electrical stimulus to help mediate MD
release [246, 247]. This anti-inflammatory aspect would be useful for other injuries as
well, since it has been repeatedly shown in multiple tissues that inflammation works in
opposition to regeneration [100, 124, 248].
Regarding inflammation outside of SCI, I wanted to briefly mention that I also
worked on a project related to Neurofibromatosis 1 (NF1), specifically investigating
Schwann cells from NF1 patients which form nerve sheath tumors and have recently been
associated with macrophages and inflammation [249]. If GMS can be used as a proinflammatory macrophage inhibitor, it might be useful in NF1 patients.

This

immunoengineering approach, where biomaterials react to and modulate the immune
response, could be a way for tissue engineering strategies to be applied to cancer
prevention and treatment, due to the nature of cancer and chronic inflammation [250,
251].
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The last direction I wanted to touch on, is that if the STS does prove itself in the
OSC, and a conduit shaped OSC, the next step would be to follow-up with minimal animal
based preclinical studies or human clinical studies. There is currently one clinically
available implantable nerve guide conduit for SCI [9, 220], which may guide the way for
future biomaterial scaffolds to be used by surgeons for SCI. There are many promising
SCI scaffold designs, and a culmination of knowledge summarized within the last year or
two. We hope that soon an implantable biomaterial such as the STS could provide SCI
patients with a reliable treatment and a quality of life that is currently unattainable.
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APPENDIX A: SUPPLEMENTAL FIGURE 1
NMR spectra of A: HepMAHA, arrows indicate methacrylate groups; B: HepSHHA,
triangles indicate thiolated groups. (Abbreviations: parts per million, ppm)
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APPENDIX B: MATLAB CODE FOR MICROSPHERE DIAMETER MEASUREMENT

Below is the Matlab code used to measure microsphere diameters. The output is radii,
and diameters were calculated in post processing. The highlighted segment is the piece
of code that changes depending on if SEM images of PLGA-MS or if Brightfield images
of GMS are being measured.
another = 1;
filename = [];
centersAll = [];
radiiAll = [];
while another == 1;
[file,path] = uigetfile;
image = strcat(path,file);
rgb = imread(image);
figure
%imshow(rgb);
%gray_image = rgb2gray(rgb);
imshow(rgb);
[centers, radii] = imfindcircles(rgb,[11 100],'ObjectPolarity','dark', 'Sensitivity',0.918);
viscircles(centers,radii);
h = viscircles(centers,radii);
%imshow(h);
for x = 1:(size(radii,1))
filename = [filename;image];
end
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centersAll = [centersAll; centers];
radiiAll =[radiiAll; radii];
prompt = 'Another? (yes = 1, no = anything besides 1, then press return)';
another = input(prompt);
if another ~=1
data = table(filename, centersAll, radiiAll);
break;
end
end
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APPENDIX C: NEURITE LENGTHS BOXPLOT
Neurite Lengths grown on MeHA, GMSF, and GMSF+NGF in SFM, M0CM, and M1CM,
with individual circles representing individual neuron lengths, X marks the average, while
the boxes and line mark the quartiles.
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APPENDIX D: HIGH RESOLUTION OSC GAPS FOR OLIGODENDROCYTE CELL
COUNT
Each page will contain one large, stitched high magnification (20x objective, 200x
magnification) image, such that an example image is given for each group. This was to
highlight the ability to count Oligodendrocytes that would otherwise be unseen in 40x
(4x objective, low resolution) images. Gaps will be outlined with a white dotted line.
Figure D-0-1: High resolution OSC example - MeHA

Olig2 DAPI
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Figure D-0-2 High resolution OSC example - HepHA

Olig2 DAPI
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Figure D-0-3 High resolution OSC example - HepHA+bFGF
Additional note, this sample was taken early on and included the green channel for
antineurofilament (NF200). In this case, the OLs would be visualized by either magenta (blue
and red overlap) or almost white coloration (red, blue, and green overlap)

NF200 Olig2 DAPI
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Figure D-0-4 High resolution OSC example - HepHA+BDNF
Addition note, the large red spherical objects are GMS, which autofluoresce in the
594nm (red) channel

Olig2 DAPI
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Figure D-5 High resolution OSC example – STS, larger
Addition note, the large red spherical objects are GMS, which autofluoresce in the
594nm (red) channel

Olig2 DAPI
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ABSTRACT
SPATIOTEMPORAL RELEASE OF GROWTH FACTORS IN A BIOMATERIALFOCUSED ORGANOTYPIC SPINAL CORD INJURY MODEL
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Degree: Doctor of Philosophy
Over 17,000 people per year in the United States sustain a spinal cord injury (SCI)
for which there is no gold standard of care and life-long complications. SCI is a complex
wound environment with various growth factors (GFs), cellular activity, and scar formation
at various timepoints. For example, basic fibroblast growth factor (bFGF) is released
immediately to protect local support cells, namely oligodendrocytes (OLs). Brain derived
neurotrophic factor (BDNF) has peak expression at 2-3 days in mice and 5-7 days in
humans, and aids axonal growth across the injury site. Incidentally this is around the
same time as M1 macrophage invasion as part of the immune response after SCI.
Growth factor (GF) delivery is a common strategy in tissue engineering, however
unbound GFs degrade quickly, and higher dosages are required to gain a therapeutic
effect. We hypothesize that GFs delivered and maintained at times that match the native
SCI response will increase the amount of neuronal reconnection and support cell
presence as compared to one or none of the individual GFs released at the same times.
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This thesis develops a spatiotemporal GF delivery system that provides bFGF
immediately and BDNF delayed, with GF bioactivity maintained via heparin-hyaluronic
acid nanofibers. Spatiotemporal release was controlled via hydrolytic degradation of
poly(lactic-co-glycolic) acid microspheres (PLGA-MS) which release bFGF immediately,
and enzymatic degradation of gelatin microspheres (GMS) which release BDNF in the
presence of collagenase, which is secreted by M1 macrophages. Both PLGA-MS and
GMS were electrospun with heparin-hyaluronic acid (HepHA) nanofibers, from which
heparin actively sequesters GFs for increased bioactivity durations.

This combined

spatiotemporal system (STS) was then evaluated in a biomaterial-focused organotypic
spinal cord (OSC) injury model for its effect on neurite reconnection as measured by
percentage recovery of injury gap and OL number per gap and density (per mm2).
Heparin-hyaluronic acid nanofibers were confirmed to sequester bioactive GFs in
culture with L929 fibroblasts and dissociated chick neurons. GMS were confirmed to only
release GFs when degraded and GMS electrospun into hyaluronic acid (HA) nanofibers
were shown to have a positive effect on chick neurons, particularly with added M1
macrophage conditioned media. Within our OSC model, STS was compared with HA and
HepHA, HepHA PLGA-MS+bFGF, and HepHA GMS+BDNF. STS had the highest
percent gap recovery and OL number compared to all other groups, however HepHA had
the highest OL density. Though there was no statistical difference between groups, the
STS is a promising biomaterial for SCI, which warrants further study.
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